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Sleep disturbances are a core and salient feature of PTSD and can maintain or 
exacerbate associated symptoms. Recent research demonstrates that cognitive-behavioral 
sleep-focused interventions improve sleep disturbances as well as PTSD symptoms. The 
present study is a randomized controlled trial comparing Cognitive Behavioral Therapy for 
Insomnia (CBT-I) to a waitlist control group. Conducted at a Veterans Affairs Medical 
Center, the study: 1) compared subjective outcome measures of sleep amongst veterans 
assigned to either a treatment group (CBT-I) or a waitlist control group; (2) examined the 
influence of the intervention on measures of PTSD, general mood and daytime functioning, 
comparing veterans in a treatment group to those in a waitlist control group and (3) examined 
  
the effect of the CBT-I intervention using objective measures of sleep for veterans included 
in the treatment arm of the study.  
Study participants were (n = 40) combat veterans who served in Afghanistan and/or 
Iraq (OEF/OIF). Participants were randomized to either a CBT-I treatment group or a wait-
list control group. Those in the treatment condition participated in four CBT-I sessions over 
six weeks. CBT-I included sleep restriction, stimulus control, cognitive restructuring, sleep 
education, sleep hygiene and imagery rehearsal therapy. All participants completed 
subjective and objective measures at baseline and post-treatment. At six weeks post 
treatment, veterans who participated in CBT-I reported improved sleep, a reduction in PTSD 
symptom severity and PTSD-related nightmares, as well as a reduction in depression and 
distressed mood compared to veterans in the waitlist control group. When controlling for 
current participation in evidence-based PTSD treatment, veterans in the CBT-I group 
reported a reduction in PTSD symptom severity while their waitlist counterparts 
demonstrated an increase in these PTSD symptoms. Veterans in the treatment group also 
reported improved objectively measured sleep quality between baseline and posttreatment.  
These data suggest that CBT-I is an effective treatment for insomnia, nightmares and 
PTSD symptoms in OEF/OIF veterans with combat related PTSD and should be used as an 
adjunctive therapy to standard PTSD treatment. 
 
     
 1 
Efficacy of a Cognitive-Behavioral Treatment for Insomnia among Afghanistan and Iraq 
(OEF/OIF) Veterans with PTSD 
The current conflicts in Iraq and Afghanistan have resulted in thousands of military 
personnel returning home psychologically damaged and wounded.  Estimates indicate that 
approximately 20% of these military personnel will develop Posttraumatic Stress Disorder 
(PTSD) post deployment (Seal, Metzler, Gina, Bertenthal, Maguen & Marmar, 2009; Hoge, 
McGurk, Thomas, Cox, Engel, & Castro, 2008).   Sleep disturbances are a core feature of 
PTSD and yet they rarely garner non-pharmacologic therapeutic attention (Harvey, Jones & 
Schmidt, 2003). Furthermore, insomnia and chronic nightmares are often resistant to standard 
pharmaceutical and psychological treatments of PTSD (Zayfert & DeViva, 2004; Galovsi, 
Monson, Bruce, & Resick, 2009). Such sleep disturbances have a significant impact on 
overall PTSD and can maintain and/or exacerbate PTSD severity (Spoormaker & 
Montgomery, 2008; Belleville, Guay, & Marchand, 2009). Recent research has shown that 
sleep-focused interventions can improve both sleep disturbances and PTSD symptoms 
(DeViva, Zayfert, Pigeon, & Mellman, 2005; Germain, Shear & Buysse, 2007; Ulmer, 
Edinger & Calhoun, 2011). 
 The purpose of the present study is to examine the effects of a brief cognitive-
behavioral intervention (four sessions) for PTSD-related insomnia in Operation Enduring 
Freedom and Operation Iraqi Freedom (OEF/OIF) veterans. To date, there have been very 
few investigations of such treatment with OEF/OIF veterans. The goals of the proposed 
intervention are to create significant improvements in sleep as well as decrease the severity 
of PTSD symptoms from which these veterans suffer. If proven to be effective, this treatment 
approach can be implementedas a time- and cost-effective adjunct to the standard PTSD 
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treatment and in turn provide a more comprehensive and high quality approach to services 
for veterans diagnosed with PTSD.  
 The present study begins with a review of the literature on posttraumatic stress 
disorder and the co-occurrence of PTSD with insomnia and chronic nightmares. Theories 
behind the co-occurrence of PTSD and sleep disturbances as well as physical and 
psychological implications are reviewed. Finally a review of cognitive behavioral therapy for 
insomnia (CBT-I) and imagery rehearsal therapy (IRT) as therapeutic interventions for 
insomnia and chronic nightmares, respectively, are discussed and examined within the 
context of current research looking at the implications for these interventions for treating 
PTSD and more specifically, combat-related PTSD.  
As stated above, this study will evaluate the implementation of a brief cognitive-
behavioral intervention for insomnia amongst OEF/OIF veterans using a randomized 
controlled trial. Veterans diagnosed with PTSD will be assigned to either a Cognitive 
Behavioral Therapy for Insomnia treatment (CBT-I) group or to a waitlist control group. 
Given the impact of poor sleep on PTSD maintenance, this study aims to determine whether 
insomnia focused treatment will result in both better sleep and decreased PTSD symptom 
severity. Subjective measures of sleep, PTSD symptom presentation and overall mood and 
daytime functioning will be collected at baseline and two weeks posttreatment for 
participants in both groups. It is hypothesized that after four sessions of CBT-I, veterans in 
the treatment group will report improved sleep, decreased PTSD symptom severity and an 
overall improvement in mood and daytime functioning compared to their waitlist 
counterparts. Objective outcome measures of sleep will also be collected for veterans in the 
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treatment group at baseline and posttreatment. If the treatment is effective, veterans should 
show improvements on these objective measures of sleep at a two-week follow-up.  
 4 
Review of the Literature 
 
Posttraumatic Stress Disorder (PTSD) 
 Posttraumatic stress disorder (PTSD) is a clinical syndrome that is characterized by 
reexperiencing of a traumatic event, avoidance of reminders of the event, and physiological 
hyperarousal symptoms that occur for more than one month after exposure to a traumatic 
event (APA, 2000). A traumatic event can include a violent crime, natural disasters or 
combat exposure, and must be associated with a threat to the integrity of the self and/or 
others. While exposure to such trauma is not rare – it is estimated that about 60% of the 
population will be witness to a traumatic event - it has been found that only 8-14% of the 
population will develop PTSD after being witness to trauma. The chances of being exposed 
to trauma and consequently developing PTSD are estimated to be higher for individuals who 
are victims of interpersonal violence (Breslau et al., 1998) and who are combat veterans (15-
30%) (Weiss et al., 1992).  
 Emerging data examining the current conflicts in Afghanistan and Iraq indicates that 
the long term effects of living through chronic trauma during combat are taking a significant 
toll on the mental health of military personnel (Tanielian et al., 2008; Hoge et al., 2008). It is 
estimated that approximately 20% of soldiers will develop PTSD, most likely during post-
deployment (Seal et al., 2009; Hoge et al., 2008). More recently, researchers argue that this 
estimate is likely to rise over time given the nature of these conflicts and the multiple 
deployments involved (Germain, Buysse, & Nofzinger, 2008). 
Sleep disturbance and PTSD. Sleep disturbance is a core feature of posttraumatic 
stress disorder (PTSD) (Spoormaker & Montgomery, 2008; Germain, Shear, Hall & Buysse, 
2007) and some have identified it as a hallmark symptom of PTSD (Ross, Ball, Sullivan, & 
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Caroff, 1989). Insomnia and nightmares are diagnostic symptoms of PTSD and symptom 
severity is related to trouble initiating sleep, maintaining sleep and nightmares (APA, 2000). 
Recent research suggests that reexperiencing symptoms of PTSD are specifically related to 
trouble initiating sleep, maintaining sleep and nightmares while hyperarousal symptoms are 
related to trouble maintaining sleep and nightmares (Babson et al., 2011). In addition to such 
sleep difficulties, sleep disordered breathing and periodic leg movement are frequently 
reported by individuals diagnosed with PTSD (Krakow et al., 2001; Maher, Rego & Asnis, 
2006). For the purposes of this research proposal however, the focus will be limited to 
insomnia and nightmares. 
Insomnia is defined as a disorder of initiating or maintaining sleep and nonrestorative 
sleep for at least one month (APA, 2000). Further, in order to meet DSM-IV criteria, the sleep 
disturbance must cause clinically significant distress or impairment in social, occupational or 
other important areas of functioning (APA, 2000). In particular, insomnia can include 
difficulties falling asleep, frequent awakenings throughout the night, and early awakenings in 
the morning. The etiology of insomnia is theorized to be dependent on predisposing, 
precipitating and perpetuating factors (Spielman, 1986).  
 Large studies conducted with both civilian and combat populations indicate that 70-
91% of participants with PTSD have difficulties falling or staying asleep (Ohayon & Shapiro, 
2000; Neylan et al., 1998). Further, results from these studies indicate a high correlation 
between PTSD symptom severity and sleep disturbances. In one research study that assessed 
sleep disturbances in participants with PTSD from the general population, it was found that 
sleep disturbances affected 70% of the PTSD participants (Ohayon & Shapiro, 2000). In 
another study, 44% of Vietnam veterans with PTSD reported difficulty falling asleep 
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(compared to 5.5% of veterans without PTSD) and 91% reported difficulty maintaining sleep 
(Neylan et al., 1998). In addition, insomnia has been found to be predictive of PTSD such 
that in one study examining accident victims, insomnia symptoms reported soon after the 
injury were associated with an increased risk for PTSD at a one-year follow-up (Koren, 
Arnon, Lavie, & Klein, 2002). More recently, researchers (Picchioni et al., 2010) assessed 
whether sleep disturbances (insomnia and nightmares) mediate the relationship between 
combat stressors and other health symptoms in Iraq war veterans. Examining the archival 
data of 576 Army veterans who responded to a packet of questionnaires three months after a 
15-month deployment, these researchers found that insomnia and nightmares partially 
mediate the relationship between combat stressors and mental health symptoms. Based on 
these findings, they concluded that sleep disturbances might contribute to and/or maintain 
other mental health symptoms frequently observed post combat such as PTSD and 
depression.   
 In contrast to the aforementioned research based on subjective measures, studies 
using objective measures have yielded more inconsistent findings (Calhoun, Wiley, Dennis, 
Means, Edinger, & Beckham, 2007; Mellman, Pigeon, Nowell, & Nolan, 2007). Objective 
measures in this research include polysomonography (PSG) or actigraphy. PSG involves 
placing surface electrodes on the scalp and face to measure physiological activity such as 
electrical activity of the heart, brain wave patterns, muscle activity, and eye movements 
while an individual is sleeping. Based on these measurements, an individual’s “sleep 
architecture” can be better understood (Harvey, Jones & Schmidt, 2003). Actigraphy, a less 
“resource intensive” process, monitors human rest/activity cycles and from this movement 
infers sleep. In particular, actigraphy includes a movement detector and memory storage on a 
 7 
watch-like device that can be worn continuously for one week or longer (Lichstein et al., 
2006). Although the actigraph cannot assess specific sleep architecture, the validity of 
actigraphy as a comparable measure to PSG has been well established (Calhoun, 2007). 
Further, the actigraphy is more sensitive than subjective sleep diaries for measuring sleep 
disturbance and fragmentation.  
Studies implementing these objective measures (PSG and Actigraphy) in laboratory 
settings have produced findings that do not consistently support subjective complaints of 
poor sleep in patients diagnosed with PTSD. In a recent study testing PSG recordings of ten 
young-adult PTSD patients within 1 to 3.5 years after a traumatic event, Habukawa and 
colleagues (2007) found that PTSD patients demonstrated significantly poorer sleep, reduced 
sleep efficiency and increased awakening from rapid eye movement (REM) sleep compared 
to the control participants. In two studies examining sleep disturbance in participants with 
combat related PTSD, increased eye movement density was associated with combat related 
PTSD (Mellman, Nolan, Hebding, Kullick-Bell & Dominguez, 1996; Ross et al., 1994). Two 
other studies (Breslau et al., 2004; Mellman et al., 2002) similarly observed REM 
interruption in PTSD patients. Breslau and colleagues (2004) compared PSG recordings of 
71 participants with lifetime PTSD to a control and found that patients with PTSD reported 
higher rates of brief arousal from REM sleep and that shifts to lighter sleep and wake were 
specific to REM sleep and significantly different than non-REM sleep. However results from 
this study failed to find objective evidence of clinically relevant sleep disturbances in patients 
with PTSD.  Such a lack of objective evidence is consistent with other findings (Klein, 
Koren, Arnon & Lavie, 2003; Lavie, 2001) that suggest subjective reports of sleep 
disturbances to be incongruent with objective measures. Mellman and researchers (2002) 
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prospectively examined twenty-one injured participants within one month of a traumatic 
event and found more PSG measured fragmented REM sleep in patients who developed 
PTSD compared to those who had not. These researchers replicated these findings, in a 
recent study examining thirty-five PTSD patients in the early aftermath of trauma (Mellman 
et al., 2007). Despite the objective findings of sleep disturbances observed in patients with 
PTSD, there still exists a discrepancy between these observations and those detected using 
subjective measures such as sleep diaries (Germain, 2009). 
With respect to the inconsistent results of these objective studies conducted in 
laboratory settings, some researchers argue that laboratory research on sleep is problematic in 
that it does not mirror the same associations and learned behaviors that occur in the natural 
sleep environment. Further, these researchers claim that patients with PTSD may actually get 
better sleep in the absence of conditioned cues for bad sleep and nightmares (Germain, Hall, 
Shear, Nofzinger & Buysse, 2006; Calhoun et al., 2007).  In a recent pilot study using in-
home PSG, Germain and colleagues (2006) found that individuals with PTSD showed longer 
sleep latency (time to fall asleep) and reduced sleep time compared to controls in a sample of 
adult crime victims. Other researchers (Calhoun et al., 2007) objectively examined sleep 
disturbance among women with PTSD in their home environment using actigraphy and 
found that relative to controls, participants with PTSD had poorer sleep efficiency, increased 
sleep latency and more restless sleep. Thus it appears that findings from home-based studies 
using these objective measures are more consistent and further support the connection 
between PTSD and insomnia. 
Chronic Nightmares in PTSD. Sleep disturbances for patients with PTSD are also 
characterized by chronic nightmares (Phelps, Forbes, & Creamer, 2008; Davis & Wright, 
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2007; Harvey, Jones, & Schmidt, 2003), which are conceptualized as one of the "re-
experiencing symptoms" of PTSD (Phelps et al., 2008). In a recent study examining 
individuals exposed to trauma, it was found that individuals diagnosed with PTSD were more 
likely to report experiences of nightmares and sleep disturbance than individuals without 
PTSD (Davis, Byrd, Rhudy, & Wright, 2007). A growing body of evidence also suggests that 
nightmares are associated with insomnia and body movements during sleep (DeViva, 
Zayfert, & Mellman, 2004; Germain & Nielsen, 2003) and that they can trigger fear about 
falling and staying asleep (Krakow et al., 2001). Consistent with this evidence has emerged a 
theoretical model that views the experience of nightmares as an independent sleep disorder 
that is comorbid with, rather than secondary to, PTSD (Moore and Krakow, 2010). Current 
research showing the negative impact of chronic nightmares on sleep supports this theory 
(Krakow et al., 2004; Krakow et al., 2001). In a recent study that prospectively examined the 
extent to which posttraumatic nightmares determined development of insomnia symptoms in 
motor vehicle accident victims, it was found that nightmares reported three months after the 
accident significantly predicted sleep maintenance problems at a one-year follow-up 
(Kobayashi, Sledjski, Spoonster, Fallon, & Delahanty, 2008).  
In research looking at the general population (Ohayon & Shapiro, 2000), participants 
with PTSD were more likely to report nightmares (19%) compared to the non- PTSD sample 
(4%). Furthermore, it has been found that the presence and severity of posttraumatic 
nightmares are associated with symptom severity (Mellman, David, Bustamante, Torres & 
Fins, 2001) and specifically severity of reexperiencing symptoms (Davis, 2009; Spoormaker 
& Montgomery, 2008). 
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 A significant amount of research has also looked at posttraumatic nightmares in 
combat populations. Within this group, chronic nightmares are considered a "persistent 
feature of chronic combat-related PTSD" (Forbes, Phelps, McHugh, Debenham, Hopwood & 
Creamer, 2003, p. 509). In studies conducted by Neylan and colleagues (1998), 52% of 
Vietnam veterans reported that they experienced nightmares compared to 5% of veterans 
without PTSD. As the research suggests, chronic nightmares are a significant component of 
the posttrauma response (Davis, 2009; Phelps et al., 2008) and are considered a “hallmark” 
of combat related PTSD (Harb, Cook, Gehrman, Gamble & Ross, 2009).  
The Effect of Insomnia and Chronic Nightmares on Functioning with PTSD. As 
independent syndromes, insomnia and nightmares have been shown to have a negative 
impact on health, functioning, and quality of life and can lead to problems with depression 
and anxiety (Rybarczyk & Mack, 2009; Germain et al., 2007). From this perspective, it 
stands to reason that sleep disturbances such as insomnia and chronic nightmares would 
serve to both exacerbate and maintain PTSD-related symptoms, particularly given that sleep 
has a "restorative function" and is important for "emotional processing" (Harvey, Jones, & 
Schmidt, 2003). Several studies have sought to further understand this impact and show that 
such sleep disturbances play a significant role and are not merely secondary posttraumatic 
stress symptoms (Krakow et al., 2004). 
As mentioned previously, Koren, Arnon, Lavie, and Klein (2002) found that sleep 
disturbances have "prognostic significance" for participants with PTSD. Specifically, they 
found that sleep complaints made one month after a traumatic event predicted PTSD one year 
later. Mellman and colleagues (2001) found that complaints of nightmares within one month 
of the traumatic event predicted greater PTSD symptom severity six weeks later. Such 
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findings support the idea that sleep disturbances (insomnia and nightmares) contribute to 
difficulties with daytime functioning. "If deprived of adequate sleep, one would expect the 
trauma survivor to be more sensitized to, reactive to, and therefore more avoidant of 
exposures to reminders of the trauma whereas a well-rested state would enhance an 
individual's capacity for coping" (Rothbaum & Mellman, 2001, p. 485).  
Further, researchers (Krakow et al., 2001) argue that both daytime and nighttime 
disturbances in adaptive functioning may interfere with the processing of the traumatic event 
as well as increase symptoms of anxiety, and that current treatment approaches to PTSD 
could benefit from evidence-based treatments used in the field of sleep medicine (Krakow et 
al., 2004).  Effective treatment of insomnia and chronic nightmares thus should result in 
improvement in daytime functioning (Morin, 2003; Rybarczyk, Stepanski, Fogg, Lopez, 
Barry & Davis, 2005; Germain, 2008). Given these findings and empirically supported 
arguments, it becomes increasingly clear that specific interventions focusing on sleep 
disturbances warrant consideration. The next section will focus on such cognitive behavioral 
conceptualizations and treatment approaches to insomnia and chronic nightmares. 
Insomnia and Chronic Nightmares 
Insomnia. As noted previously, insomnia is defined as a disorder of initiating or 
maintaining sleep and nonrestorative sleep for at least one month (APA, 2000). Morin (2004) 
suggests that in addition to these APA diagnostic criteria, clinicians should be in the habit of 
identifying specific “markers” that will help in making more clinically meaningful insomnia 
diagnoses. He specifically identifies these markers as (1) the amount of time required to fall 
asleep and (2) the duration of awakenings. Such specificity, he suggests, will assist in 
clinicians’ understanding of the nature of a patient’s insomnia. He also asserts that total sleep 
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time is not a sufficient indicator of “non restorative sleep” because of individual differences 
in sleep needs. Rather, inadequate sleep (insomnia) develops as a result of fragmented and 
unconsolidated sleep, which can be better understood when assessing for these markers. 
Within the past two decades, a diathesis-stress conceptualization of insomnia has 
become the standard theoretical framework from which researchers examine and treat 
insomnia (Spielman, 1986; Webb, 1988; Drake, Roehrs, & Roth, 2003; Morin, 2004). 
According to this model, “predisposing factors” (i.e. a predisposition to a sensitive 
sympathetic arousal system) together with “precipitating events” (i.e. a stressful event such 
as a trauma or a medical condition) contribute to the development of a sleep disturbance such 
as insomnia. Further this model posits that this insomnia is maintained by “perpetuating 
mechanisms.” In particular, cognitive and behavioral factors that emerge with the 
development of insomnia sustain and perpetuate insomnia. Based on this theory, researchers 
hold that insomnia treatment must in turn focus on these perpetuating mechanisms (Morin, 
2004; Spielman, 1986; Edinger, 2005). Specifically, it is argued that treatment of insomnia 
should target beliefs about sleep and habits related to an individual’s sleep behaviors that 
maintain abnormal sleep patterns. The specifics of such an intervention will be further 
detailed below. 
Insomnia Intervention. To date, the most common treatment approach for insomnia 
has been pharmacotherapy (Edinger et al., 2009). However, although it has been found that 
pharmaceutical approaches may be effective in the short term, long-term use has been found 
to involve a risk of dependency and tolerance (National Institutes of Health, 2005). 
Alternatively, psychological approaches to insomnia (cognitive and behavioral) designed to 
focus on sleep disruptive beliefs and habits have proven to be as effective as 
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pharmacotherapy in the short-term and more effective in the long term (Smith et al., 2002; 
Sivertsen et al., 2006). In a randomized controlled trial comparing cognitive behavioral 
therapy for insomnia (CBT-I) and Zopiclone (Lunesta), Sivertsen and colleagues (2006) 
found that at a six-month follow-up CBT-I participants increased their sleep efficiency (the 
ratio of time asleep to time in bed) while those participants receiving Zopiclone showed a 
decrease in sleep efficiency. Furthermore, a recent review of thirty-seven insomnia treatment 
studies conducted from 1998-2004 (Morin et al., 2006) confirmed the efficacy of CBT-I and 
indicated that such a treatment approach leads to sleep improvements that persist in the long 
term. A more current meta-analysis reviewing insomnia treatment studies published from 
1990-2009 (Okajima, Komada, & Inoue, 2011) that utilized both subjective and objective 
measures found further support for the efficacy of CBT-I although the objective measures 
showed more modest treatment effects relative to the subjective outcomes. (This finding is 
consistent with the research mentioned earlier regarding the discrepancies observed between 
objective and subjective measures of sleep.)  
Overall these findings indicate that CBT-I is an effective cognitive- behavioral 
approach to treating insomnia. Cognitive-behavioral treatment of insomnia in this research 
includes a multi-component approach including behavioral and cognitive techniques for 
addressing insomnia.  Such an approach involves the acquisition of self-management skills 
(Bastien, Morin, Ouellet, Blais, & Bouchard, 2004) and has shown to be as effective as 
medication with longer lasting effects (Goodie, Isler, Hunter & Peterson, 2009). 
Cognitive-behavioral treatments for insomnia (CBT-I) combine sleep restriction 
(restricting time spent awake in bed) and stimulus control (restricting sleep-incompatible 
activities and enforcing a consistent sleep-wake schedule) as a means of standardizing an 
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individual’s sleep schedule (Edinger & Carney, 2008) and consolidating sleep over a shorter 
period of time in bed (Morin, 1993). As mentioned previously, insomnia is a disorder of 
fragmented and disrupted sleep, not necessarily a disorder of too little sleep. As such, the 
primary goal of CBT-I is to consolidate a patient’s sleep so that it is more efficient and more 
restorative. Relaxation training, sleep hygiene (focusing on health practices and 
environmental factors) and cognitive restructuring (Morin, 2003; Rybarczyk et al., 2005) are 
additional treatment components of CBT-I.  
Studies implementing this multi-component treatment approach indicate greater 
efficacy than single component treatments (Morin et al., 1994; 2006). The majority of the 
evidence supporting this claim comes from studies conducted with patients diagnosed with 
primary insomnia. Edinger and colleagues (2001) tested the efficacy of a six-week group 
treatment of insomnia for seventy-five participants diagnosed with primary insomnia. The 
study compared CBT-I, progressive muscle relaxation (PMR), and a sham behavioral 
intervention. Relative to patients in the PMR group and the placebo group, patients who 
received CBT-I demonstrated greater sleep efficiency improvements and significant 
outcomes. In an effectiveness trial comparing outcomes of primary care patients treated with 
CBT-I to those in a waitlist control, Espie and colleagues (2001) found CBT-I to be superior 
on primary (sleep latency and wakefulness during the night) and secondary outcome 
measures (76% of the participants originally taking hypnotic medication had stopped 
completely at posttreatment). As the efficacy of CBT-I for primary insomnia became 
increasingly more established, Edinger and colleagues (2007) sought to determine the 
optimal amount of sessions needed for CBT-I to be effective. In a randomized clinical trial, 
eighty-six adults diagnosed with primary insomnia were given individual sessions of CBT-I 
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for one, two, four or eight weeks. Results from this study indicate that four individual, bi-
weekly sessions represents the optimal dosing for CBT-I. 
 As is evident, the literature supports this non-pharmaceutical approach as a viable and 
favorable alternative for treating patients with primary insomnia. The story is somewhat 
different with respect to insomnia that occurs along with a psychological or medical disorder. 
Until recently, sleep disorders in the context of psychological or medical disorders have been 
viewed as secondary. For example, in patients with PTSD, sleep disorders are most often 
treated as a condition that is an underlying symptom of PTSD. Thus it is believed that if the 
PTSD is treated, the sleep disorder symptoms will resolve (Spoormaker & Montgomery, 
2008). As stated previously, it is now commonly accepted that insomnia and daytime 
functioning can have a bi-directional affect on each other and thus the etiology of insomnia 
or a concurrent disorder is difficult to determine (Lichstein, Wilson, & Johnson, 2000; 
Stepanski & Rybarczyk, 2006). As such, there has been a shift in the conceptualization of 
insomnia from a syndrome that is "secondary" to other disorders to one that is "comorbid" 
with other disorders (Stepanski & Rybarczyk, 2006). 
Along with this recent paradigm shift has been a surge in research looking at 
treatment efficacy for insomnia that affects both nighttime and daytime functioning with 
patients for whom insomnia is comorbid with other psychological or medical disorders 
(Lichstein, Rybarczyk, & Dillon, in press; Peterson, Rumble & Benca, 2008; Smith, Huang 
& Manber, 2005). In a recent review, Smith, Huang & Manber (2005) concluded that CBT-I 
is useful in both improving sleep and psychological and medical conditions. In a randomized 
waitlist control study testing the efficacy of four sessions CBT-I with forty-four older adults 
diagnosed with insomnia associated with a medical or psychiatric condition, Lichstein and 
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colleagues (2000) found that wake after sleep onset, sleep efficiency and overall quality of 
sleep were significantly improved at post treatment and at a three-month follow-up. In 
another study that randomly assigned sixty patients with insomnia comorbid with chronic 
pain to CBT-I or a waitlist control condition, Currie and colleagues (2000) found that 
patients in the CBT-I condition were significantly improved on self-report measures of sleep 
onset latency, wake after time asleep onset, sleep efficiency, and sleep quality and showed 
less nighttime motor activity as measured by actigraphy.  Similarly, a study of CBT-I 
administered to ten women with non-metastic breast cancer revealed significant 
improvements in total wake time and sleep efficiency as evidenced by both self-report and 
polysomnographic data (Quesnel, Savard, Simard, Ivers, & Morin 2003). Moreover, results 
from this study indicate an association between CBT-I and significant improvements of 
mood, general and physical fatigue, and global dimensions of quality of life. Dirksen and 
Epstein (2008) found that CBT-I led to significant improvements in fatigue, depression, trait 
anxiety, and quality of life for seventy-two women who were three months posttreatment for 
breast cancer. Finally, Watanabe and colleagues (2011) found that in patients with residual 
depression and refractory insomnia, cognitive- behavioral therapy for insomnia combined 
with treatment as usual (i.e. medication) produced greater treatment effects for insomnia and 
depression over treatment as usual. 
Further evidence of the efficacy of CBT-I for comorbid insomnia is indicated in a 
study of fifty-one older adults with comorbid insomnia associated with a medical illness. 
Rybarczyk and colleagues (2002) compared the effects of CBT-I, relaxation training and a 
waitlist control group. At posttreatment, CBT-I participants demonstrated greater 
improvements compared to waitlist participants on self-report measures of sleep efficiency, 
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wake after sleep onset time and overall sleep quality. Participants in the relaxation condition, 
on the other hand, had significantly greater improvement for total sleep time. Further, more 
CBT-I participants (54%) met criteria for clinically significant improvement at posttreatment 
and at follow-up compared to the relaxation group (34%) and the waitlist control group (6%). 
None of the interventions were associated with improvement of sleep continuity as measured 
by actigraphy.  
These findings were further supported in a more recent study (Rybarczyk et al., 2005) 
in which ninety-two older adults with a medical condition (osteoarthritis, coronary artery 
disease, or pulmonary disease) were randomly assigned to classroom CBT-I or stress 
management and wellness (SMW) training (placebo condition). Compared to the SMW 
group, participants in the CBT-I condition showed significant improvement on a variety of 
self-report measures including sleep efficiency, sleep latency, time awake after sleep onset, 
naps per day, daytime impairment caused by sleep problems, global measures about sleep 
and beliefs about sleep. In addition, the treatment efficacy rate for CBT-I was 78% compared 
to 24% for the SMW condition.   
Taken together, these studies support the theory that cognitive-behavioral treatment 
for insomnia is beneficial for patients suffering from both insomnia as well as psychological 
or medical conditions. Furthermore, they provide evidence that CBT-I for comorbid 
insomnia may affect secondary outcomes such as depression, anxiety, fatigue and global and 
cognitive dimensions of quality of life (Lichstein, Rybarczyk, & Dillon, in press; Dirksen & 
Epstein, 2008; Manber, Edinger, Gress, San Pedro-Salcedo, Kuo, & Kalista, 2008; 
Rybarczyk et al., 2005; Bastien et al., 2004).  
CBT for Insomnia (CBT-I) Nuts and Bolts. 
 18 
 Sleep Scheduling. Sleep scheduling includes a combination of stimulus control and 
sleep restriction (Morin & Espie, 2004) and is considered “the heart of the entire 
intervention” (Morin, 1993). Stimulus control is based on the assumption that individuals 
with insomnia may engage in behaviors in the bed and bedroom that are incompatible with 
sleep. Specifically, when the bedroom is a place for activities such as reading, watching 
television, eating, and talking on the phone, to name a few, difficulties with sleep may be 
maintained by the association of the bedroom as a place of arousal rather than sleep (Bootzin, 
1972; Engle-Friedman, Bootzin, Hazlewood & Tsao, 1992). Likewise, lying in bed awake 
(trying to go to sleep, waking up in the middle of the night or early in the morning) can 
further strengthen the association of bedroom and wakefulness (Morin & Espie, 2004). 
Stimulus control treatment thus focuses on creating the bedroom as a stimulus for sleep. 
Patients are instructed to get out of bed if they are unable to fall asleep in 15-20 minutes, to 
avoid using the bedroom for any activities other than sleep and sexual activity, to lie down to 
sleep only when tired and to get up at the same time everyday.  
 Sleep restriction concentrates on helping the patient make their sleep more efficient. 
That is, sleep restriction attempts to reduce awakenings, have patients’ time in bed be more 
reflective of the amount of time they are actually sleeping, and thus make sleep a more 
compressed, continuous, and efficient process (Spielman, Saskin, & Thorpy, 1987).  For the 
patient with insomnia, sleep is often fragmented and thus one of the main goals of sleep 
restriction is to consolidate a patient’s sleep over a shorter amount of time in bed (Morin, 
1993). Sleep restriction treatment is first conducted by assessing how much time a patient is 
actually sleeping through the night otherwise known as total sleep time (TST). Once the TST 
is determined a sleep window can be established. The patient’s rising time is used as an 
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anchor and the time at which the patient goes to bed is determined by subtracting the TST 
from this anchor (Spielman, Saskin, & Thorpy, 1987; Morin 2004).  
 Sleep Hygiene. Sleep hygiene refers to behavioral and environmental changes that 
patients can make to facilitate good sleep. Lifestyle habits such as drinking caffeine and 
alcohol at night or exercising close to bedtime are typical behaviors that can interfere with 
sleep. Similarly, room temperature, lighting, and volume can also affect sleep. Thus sleep 
hygiene focuses on eliminating such factors that hinder rather than promote good sleep. 
Cognitive Restructuring. Research indicates that patients with insomnia hold 
maladaptive and dysfunctional cognitions about sleep (Morin, Stone, Trinkle, Mercer & 
Remsberg, 1993; Morin & Espie, 2004). In particular, these patients worry about the negative 
consequences of insomnia and express unrealistic expectations about sleep needs as well as 
hopelessness and helplessness about the lack of control they have of their sleep. It has been 
shown that these maladaptive beliefs are associated with insomnia and that when changed 
they are significantly associated with sleep improvement (Edinger, Wohgemuth, Radtke, 
Marsh, & Quillian, 2001a; 2001b). Cognitive restructuring thus aims to change these 
dysfunctional beliefs by identifying and challenging these thoughts. 
Combined, these four components (stimulus control, sleep restriction, sleep hygiene 
and cognitive restructuring) make up the CBT-I protocol as outlined by Morin (1993). The 
next section will focus on the theory and treatment approaches for chronic nightmares. 
Chronic Nightmares. 
Three-Factor Model of Post-Traumatic Nightmare Development and Maintenance.  
Based on the cognitive-behavioral model of insomnia discussed above, Davis (2009) 
suggests a three-factor model in understanding post-trauma nightmares that similarly 
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includes predisposing, precipitating and perpetuating factors. According to Davis (2009) 
predisposing factors include any pretrauma history that might make an individual more 
vulnerable to developing nightmares. Precipitating factors may include the trauma itself or 
the response to the traumatic event. Finally, as Krakow and Zadra (2006) argue, the factors 
that cause chronic nightmares to develop may not be the same factors that make them 
chronic. A host of cognitive, behavioral as well as physiological factors may be at play in 
maintaining and perpetuating these nightmares. This model is consistent with the current 
research mentioned earlier that views chronic nightmares as an independent sleep disorder. 
Treatment of Chronic Nightmares. Until recently, treatment for chronic nightmares 
has typically been addressed using psychopharmacology (Raskind et al., 2003; 2007; Krystal 
& Davidson, 2007; Gehrman & Harb, 2010). More recently however, Imagery Rehearsal 
Therapy (IRT) has emerged as an effective and time-efficient intervention for treating 
chronic nightmares. Consistent with the theoretical model of chronic nightmares as an 
independent sleep disorder, IRT is based on a cognitive-behavioral paradigm that posits that 
nightmares are a “learned behavior disorder” akin to sleep disorders and that nightmares are 
especially prevalent in individuals with poor imagery capabilities (Moore & Krakow, 2010). 
In the general population, chronic nightmares have been successfully treated using imagery 
rehearsal therapy (IRT) both independently and as an adjunct to CBT-I (Krakow et al., 2000; 
Lamarche & DeKoninck, 2007). Standard IRT protocol (Krakow & Zadra, 2010) covers four 
sessions in which the first two sessions serve as introduction and education about nightmares, 
their connection to insomnia and consequent effects on daytime functioning and other 
disorders such as PTSD. During this first part of the protocol the patient is introduced to the 
concept of imagery and imagery skills are practiced and rehearsed at home. For the last two 
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sessions, the focus is on the nightmares themselves with an emphasis on attempting to 
change “the learned behavior”, that is the nightmare. Specifically, patients are asked to 
choose a nightmare of moderate distress (for initial sessions) and then to change that 
nightmare. Patients are given non-directive instructions and told to “change the nightmare 
anyway you wish” (Niedhardt et al., 1992). Next patients are instructed to write down the 
changed dream and then rehearse this rescripted dream in imagination for 5-20 minutes daily. 
Protocol stresses the notion that IRT is not meant to be an exercise in exposure; in fact this is 
highly discouraged as the goal is not to create arousal in patients. Studies indicate that IRT is 
effective in reducing nightmare distress and nightmare frequency and that these changes are 
maintained at follow-up (Krakow & Zadra, 2006; Krakow et al., 2001; Germain, 2003).  
 Given the centrality of insomnia and nightmares to the functioning of individuals 
diagnosed with PTSD, one might assume that these well-validated treatments have already 
been well-established in the research and treatment of PTSD-related sleep disturbances. The 
current state of the research, however, suggests something different. 
Insomnia and Nightmare Intervention for PTSD  
Historically, insomnia intervention has not been the first line of treatment or even 
included as a specific component of PTSD treatment. Despite the DSM-IV definition of 
PTSD, sleep disturbances are often considered secondary to PTSD, and as a result, insomnia 
and chronic nightmares have not garnered much therapeutic attention on their own (Harvey, 
Jones, & Schmidt, 2003; Krakow et al., 2007). However, recent research indicates that 
evidence-based treatments for PTSD are not sufficient in significantly reducing sleep 
disturbances for this population (Galovski, Monson, Bruce, & Resick, 2009). To date, 
pharmacological approaches have been the treatment of choice for PTSD-related sleep 
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disturbances (Lamarche & DeKoninck, 2007). Although some studies indicate the efficacy of 
pharmaceutical treatments, as discussed previously, there is little evidence suggesting long-
term efficacy of medications for insomnia and the risk of dependence is greater for those who 
use medications for prolonged periods (Morin & Espie, 2004). Researchers (Krakow et al., 
2007; DeViva, Zayfert, Pigeon, & Mellman, 2005) argue that the frequency with which 
trauma survivors diagnosed with PTSD experience insomnia and nightmares, often after 
receiving CBT treatment for PTSD, warrants specific clinical non-pharmacological attention.  
 Recent research in support of this argument has shown that sleep-focused 
interventions for individuals with PTSD can indeed reduce sleep disturbances as well as 
reduce overall PTSD symptoms (Krakow et al., 2001a; 2001b; 2006; Forbes et al., 2003; 
Germain & Nielsen, 2003; Germain et al., 2007). These studies have implemented IRT alone 
or a combination of CBT-I and IRT (Germain et al., 2007; Krakow et al., 2001, 2006). Table 
1 summarizes this research. 
 IRT for Trauma Related Nightmares. Krakow, Hollifield and colleagues (2001) 
found that implementation of IRT was associated with a significant reduction in number of 
nightmares per week, improved sleep, and decreased mean PTSD severity from severe to 
moderate, and that these effects were maintained at three and six month follow-up. Extending 
this research, Krakow, Johnston and colleagues (2001) looked at the effect of IRT, sleep 
hygiene, stimulus control, sleep restriction, and cognitive restructuring as an intervention for 
trauma-related insomnia. This study of sixty-two crime victims found that sleep quality and 
insomnia severity improved significantly after treatment and that these improvements were 
associated with significant, moderate effects for measures of PTSD severity, anxiety and 
depression.  
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Combination of CBT-I and IRT for Trauma Related Insomnia and Nightmares. 
In a recent pilot study, seven adult victims of violent crimes (three men and four women) 
with a diagnosis of PTSD received one 90-minute session that combined CBT-I and IRT 
(Germain et al., 2007). At posttreatment (six to eight weeks after the intervention), patients 
reported clinically significant improvements in sleep quality and significant improvements in 
overall daytime PTSD symptom severity. 
Such findings provide promising evidence as to the efficacy and efficiency of this 
specialized treatment for individuals with PTSD. Although the research in this area is 
limited, the work that has been conducted suggests that such specific treatments are 
beneficial, especially when sleep disturbance is not addressed by traditional cognitive 
behavioral treatments of PTSD. The studies reviewed in this section, however,  do not 
include participants diagnosed with PTSD related to being in a war-zone. The following 
section discusses recent research examining the effects of cognitive-behavioral treatments of 
insomnia and traumatic nightmares for veterans diagnosed with combat-related PTSD. These 
studies have implemented IRT alone, CBT-I alone or a combined approach using both CBT-I 
and IRT. 
Insomnia and Nightmare Intervention for Combat-Related PTSD  
IRT for Combat-Related Posttraumatic Insomnia and Nightmares. The research 
on psychological treatment of sleep disturbances experienced by individuals with combat-
related PTSD is limited as well. Chronic nightmares have received a recent surge in research 
interest in the combat population. In a pilot study, Forbes, Phelps, McHugh and colleagues 
(2001; 2003) examined the efficacy of group administered imagery rehearsal therapy (IRT) 
on posttraumatic nightmares in twelve male Vietnam veterans with chronic PTSD. Treatment 
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consisted of six, weekly, 90-minute sessions. Participants, ranging in age from 45-50, 
completed self-report measures and sleep diaries for one week prior to treatment, 
posttreatment, and at a three and twelve-month follow-up. At the end of treatment, and at the 
three and twelve-month follow-up, findings indicated significant reductions in nightmare 
frequency and intensity. Further, improvements in overall PTSD, depression and anxiety 
were maintained at twelve months posttreatment.   
In a case series that followed, eleven soldiers deployed to Iraq with a primary 
complaint of chronic nightmares, Moore and Krakow (2007) found that four individual 
sessions of IRT were associated with clinical improvements of acute nightmares, 
posttraumatic stress symptoms, and insomnia severity. Lu and colleagues (2009) in an 
uncontrolled study of fifteen male veterans from various combat theaters found that IRT was 
not associated with immediate post-treatment improvements. However, when assessed at a 
three-month follow-up, veterans reported a decrease in nightmare frequency and reduction of 
PTSD symptoms. Similarly, the efficacy of IRT was studied using chart review of VA 
medical records of veterans seeking treatment for chronic nightmares. In this analysis, IRT 
treatment completers reported significant decreases in frequency and intensity of nightmares, 
severity of insomnia and PTSD symptoms (Nappi, Drummond, Thorp & McQuaid, 2010).  
CBT-I for Combat-Related Posttraumatic Insomnia and Nightmares. Insomnia 
interventions for combat related PTSD have received even less attention. One recent study 
conducted at the VA in Ann Arbor, Michigan (Perlman, Arnedt, Earnheart, Gormon, & 
Shirley, 2008) looked at a group administration of CBT-I for twenty veterans (ages ranging 
from 26-84 years) with chronic insomnia who had been diagnosed with at least one medical 
condition (chronic pain, hypertension, gastroesophageal reflux disorder, diabetes, lung 
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disease, bladder incontinence, liver disease) and at least one psychiatric disorder (depression, 
bipolar disorder, PTSD, GAD, panic, social anxiety). (It should be noted that the only 
exclusion criteria for this study was a diagnosis of PTSD with recurrent combat related 
nightmares.) The CBT-I groups were conducted weekly over eight to ten weeks and lasted 75 
minutes. Findings from this group administration, based on self-report measures, indicated 
significant improvement of sleep efficiency as well as total sleep time. Furthermore, patients 
reported significant improvements in daytime functioning (less depression, anxiety and 
fatigue). 
Combination of CBT-I and IRT for Combat-Related Posttraumatic Insomnia 
and Nightmares. Four more recent studies have examined a combined treatment approach of 
CBT-I and IRT with combat veterans. In a 2007 pilot study investigating the efficacy of 
seven to eight sessions of combined CBT-I and IRT in a sample of eleven Iraq war veterans, 
significant reductions were observed in nightmare frequency, PTSD symptoms and sleep 
quality (Harb et al., 2009). In 2009, Swanson and colleagues assessed a combined ten-session 
CBT-I/IRT group intervention with nine veterans of various combat theaters diagnosed with 
PTSD. Posttreatment, veterans who participated in treatment reported improvement in sleep 
quality and a reduction in insomnia severity, nightmare frequency and nightmare distress 
although no significant decreases in PTSD symptoms were reported. In another randomized 
controlled trial in which sixty-one Vietnam veterans were randomized to either an IRT 
treatment condition or an active comparison condition including psychoeducation about 
PTSD and nightmares as well as elements from Morin’s CBT-I protocol (2006), a change in 
sleep quality and PTSD symptom severity was found for both groups however veterans who 
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received IRT, did not improve more than veterans in the comparison group on outcome 
variables of nightmare frequency and sleep quality (Cook et al., 2010).  
More recently, using a randomized parallel group experimental design, Ulmer and 
colleagues (2011) examined the efficacy of a combined intervention for combat-related sleep 
disturbances in veterans from various combat theaters. Specifically, participants randomized 
to the treatment group received six bi-weekly, one-hour, individual sessions of CBT-I and 
IRT (the first three sessions focused on CBT-I while the last three sessions were dedicated to 
IRT). The control group received treatment as usual by their primary care physician. Relative 
to the control group, veterans who participated in the intervention reported reductions in 
PTSD symptoms and insomnia severity, improvements in sleep quality and sleep diary 
outcome measures. However the intervention did not produce a significant treatment effect 
for depression as was predicted. 
Given the strong evidence for the efficacy of CBT-I treatment for individuals with 
PTSD, it is clear that continuing to examine and understand the effects of such an 
intervention for combat-related PTSD is an important area of research. To date, very few 
studies have looked at cognitive-behavioral approaches for insomnia and nightmares in this 
population and only a handful of studies have researched this treatment approach with the 
OEF/OIF veteran population. 
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Table 1.  
 
Articles assessing behavioral treatments (CBT-I and IRT) for posttraumatic insomnia and nightmares 
 
Author, year n Participants Control 
Group 
Treatment Objective 
Measures 
Used 
Results 
Krakow et al. 
(2001) 
62 Crime 
victims 
No Ten hour group treatment of 
IRT with sleep hygiene, 
stimulus control and sleep 
restriction. 
No Significant improvements in sleep 
quality and decreases in sleep 
impairment, nightmare frequency, PTSD 
symptom severity and depression at 3-
month follow-up.  
Krakow et al. 
(2001) 
168 Female 
victims or 
rape or 
other 
sexual 
assault. 
Yes Three sessions of IRT (two 3-
hour sessions spaced 1 week 
apart with a 1-hour follow-up 3 
weeks later). 
No Significant decrease in chronic 
nightmares, PTSD symptom severity 
and improvement in sleep quality. 
Germain et 
al., 2007 
7 Male and 
female 
crime 
victims 
No One 90-minute individual 
session: IRT, Stimulus control 
& Sleep Restriction 
No Posttreatment (6-8 weeks) significant 
improvements found in sleep quality & 
overall PTSD symptom severity 
Forbes et al., 
2001; 2003 
12 Vietnam 
veterans 
No Group administered IRT (six 
weekly, 90-minute sessions) 
No Significant reductions in nightmare 
frequency and intensity. 
Moore & 
Krakow, 2007 
11 Soldiers 
deployed to 
Iraq 
No Four individual sessions of IRT No Improvements of acute nightmares, 
posttraumatic stress symptoms, 
insomnia severity 
Lu et al., 2009 15 Male 
veterans of 
various 
combat 
theaters 
No Six week, 90-minute IRT group 
of 3-5 veterans 
No No significant post-treatment 
improvements. However, at 3-month 
follow-up, found significant decreases in 
nightmare frequency and reduction of 
PTSD symptoms 
Nappi et al., 58 Veterans of No Four to five treatment sessions  Significant decreases in frequency and 
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2010 different 
eras of 
service 
of IRT lasting 1 (individual) or 
2 (group) hours. 
intensity of nightmares, severity of 
insomnia, and PTSD symptoms 
Perlman et al., 
2008 
20 Veterans of 
different 
eras of 
service 
No Group administered CBT-I. 
Eight-ten weekly sessions (75 
minutes each). 
No Significant improvement of sleep 
efficiency and total sleep time. 
Significant improvements also seen in 
daytime functioning (less depression, 
anxiety and fatigue).  
Harb et al., 
2009 
11 Iraq war 
veterans 
No Six session of combined CBT-I 
and IRT. 
No Significant reductions in nightmare 
frequency, PTSD symptoms and sleep 
quality 
Swanson et 
al., 2009 
9 Veterans of 
various 
combat 
theaters 
No Ten sessions of combined CBT-
I and IRT 
No Significant improvement in sleep quality 
and reduction in insomnia severity, 
nightmare frequency, and nightmare 
distress. 
Cook et al., 
2010 
61  Vietnam 
veterans 
Yes Treatment condition (IRT) vs. 
active (psychotherapy) 
comparison (psychoeducation 
about PTSD and nightmares 
with elements of CBT-I) 
No Significant change in sleep quality and 
PTSD symptom severity found for both 
groups. Veterans who received IRT did 
not improve more than veterans in the 
comparison group on variables of 
nightmare frequency and sleep quality. 
Ulmer et al., 
2011 
20 Veterans of 
various 
combat 
theaters 
Yes Six bi-weekly, 1-hour 
individual sessions (3 sessions 
of CBT-I and 3 sessions of IRT, 
in that order) or waitlist control. 
No Significant reductions in PTSD 
symptom severity and insomnia severity 
compared to a wait list control. 
Significant improvements in sleep 
quality and decreases in sleep onset 
latency and wake after sleep onset. 
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PTSD and Operation Enduring Freedom/Operation Iraqi Freedom Military Personnel 
Statement of the Problem. To date, it is estimated that 1.64 million U.S. troops have 
been deployed for Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) in 
Afghanistan and Iraq, respectively (Tanielian et al., 2008). Unlike previous U.S. wars, these 
two conflicts are unique in that soldiers are surviving at rates that at one time would have 
been inconceivable. Advances in trauma care along with improved body armor are allowing 
military service members to survive once fatal experiences. Unfortunately, this survival 
comes at a cost.  
 It is estimated that roughly 20% of these military personnel will struggle with 
Posttraumatic Stress Disorder (PTSD) after they return home from deployment (Hoge, 
McGurk, Thomas, Cox, Engel, & Castro, 2008). Sleep disturbances are a core feature of 
PTSD and are exhibited as both re-experiencing symptoms (nightmares) and hyperarousal 
symptoms (insomnia). The gold-standard treatment for combat related PTSD is considered 
exposure therapy (Prolonged Exposure and Cognitive Processing Therapy) and these 
interventions have been shown to have beneficial effects on PTSD severity (Karlin, Ruzek, 
Chard, Eftekari, Monson, Hembree, Resick & Foa, 2010). However, in and of itself exposure 
therapy does not seem to have a strong treatment effect on PTSD-related sleep disturbances 
and insomnia often persists in the absence of nightmares and hypervigilance (Zayfert & 
DeViva, 2004). This suggests that these PTSD related sleep disturbances might develop into 
independent disorders that demand intervention above and beyond standard exposure 
therapy. In fact, research shows that such sleep disturbances may even maintain and/or 
exacerbate PTSD symptom severity and thus become a barrier to standard treatment 
(Spoormaker & Montgomery, 2008).  
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As discussed here, treatments for PTSD-related sleep disturbances have proven to be 
effective at reducing posttraumatic insomnia and nightmares as well as daytime PTSD 
severity. This proposal seeks to examine the efficacy of such an intervention implemented at 
the Hunter Holmes McGuire Veterans Administration Medical Center with a focus on 
OEF/OIF veterans, given the relative paucity of research assessing cognitive- behavioral 
insomnia treatments for insomnia with this specific population.  
 The research supporting the efficacy of CBT-I for individuals with PTSD, along with 
the growing number of military personnel returning home with PTSD, demands an increased 
focus on the treatment of this population. To date, research examining the effects of insomnia 
treatment in combat-related PTSD is limited in several ways. The pilot studies noted above 
(Forbes et al, 2001; Moore and Krakow, 2007) included a small sample size and did not have 
a control group; thus it is not possible to infer a causal relationship between the treatment and 
symptom changes. The group intervention conducted at the VA (Perlman et al., 2008) was 
similarly limited in that there was no control group and that PTSD related nightmares were 
considered exclusionary criteria. Two studies cited using a combined treatment approach of 
CBT-I and IRT (Harb et al., 2009; Swanson, Favorite, Horin & Arnedt, 2009) were also 
limited in their small sample size and uncontrolled design. To date, only one study has used a 
randomized control design to examine the efficacy of a combined intervention approach to 
treating combat-related sleep disturbances (Ulmer et al., 2011).  This study demonstrated the 
efficacy of combined treatment with a veteran combat population but was limited due to its 
small sample size (n =22) and lack of objective measures. The proposed research should add 
to the literature by addressing these limitations.  
  31
The investigation examines whether Cognitive Behavioral Therapy of Insomnia  
(CBT-I; Morin, 1994; 2006) combined with an abbreviated protocol of Imagery Rehearsal 
Therapy (IRT; Krakow et al., 2000; 2006) is beneficial and therapeutic for OEF/OIF veterans 
diagnosed with PTSD for whom insomnia is a major concern. The CBT-I protocol included 
four individual sessions addressing cognitive and behavioral issues related to sleep and 
nightmares. Past studies, although limited, have demonstrated the efficacy of this combined 
intervention with significant improvements in sleep and reductions in PTSD severity 
(DeViva, Zayfert, Pigeon, & Mellman, 2005; Germain, Shear, Hall, & Buysse, 2007; Harb et 
al., 2009; Ulmer et al., 2011). If proven to be effective, future research should seek to include 
veterans of all conflicts.  
As described in more detail below, this study will be a randomized control trial, and 
intervention components will include CBT-I integrated with elements of IRT. Further, the 
research will be conducted in a Veterans Affairs Medical Center with recently returning 
troops, one of only a few studies within this line of research. Based on the literature 
reviewed, it is believed that effective treatment of insomnia and chronic nightmares should 
result in improvement in PTSD symptoms and daytime functioning in addition to an 
improvement in sleep quality and a decrease in frequency and intensity of nightmares 
(Morin, 2003; Rybarczyk et al., 2005; Germain, Buysse, & Nofzinger, 2008). 
Aims and Hypotheses. The specific aims of this study are to: (1) using a randomized 
control trial, compare subjective outcome measures of sleep amongst OEF/OIF veterans 
assigned to either a treatment group (CBT-I) or a waitlist control group; (2) examine the 
influence of the intervention on subjective measures of PTSD, general mood and daytime 
functioning, comparing OEF/OIF veterans in a treatment group to those in a waitlist control 
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group and; (3) to examine the effect of a CBT-I intervention using objective measures of 
sleep for these veterans included in the treatment arm of the study. 
Based on the literature and the aims of this study, it was hypothesized that: (1) 
veterans in the treatment group would report improvement on self-report sleep measures 
(sleep diaries and sleep related questionnaires) compared to the wait-list control group. These 
outcomes broadly included sleep quantity, sleep quality, and insomnia severity. In addition it 
was hypothesized that participants in the treatment group would show significant reductions 
in dysfunctional beliefs and attitudes about sleep compared to waitlist controls. (2) Relative 
to the waitlist-control condition, individuals assigned to the treatment condition would show 
reductions in PTSD severity and improvements in mood and daytime functioning This 
hypothesis is based on the literature indicating that insomnia has significant causal effects on 
psychosocial functioning, physical functioning and quality of life; and (3) Participants in the 
treatment group would show increased sleep quantity (total sleep time) and quality (sleep 
onset latency, wake after sleep time, sleep efficiency), according to objective measures, 
following treatment. It was expected that they would maintain these treatment gains at the 
follow-up assessments. 
Methods 
Objectives of Proposed Study 
 The primary goal of this study is to examine whether Morin’s (2003) Cognitive 
Behavioral Therapy for Insomnia (CBT-I) combined with elements of Imagery Rehearsal 
Therapy (IRT) is a useful therapeutic adjunct for OEF/OIF veterans with PTSD. 
 This study was approved by both Virginia Commonwealth University’s Institutional 
Review Board under the title “Effects of a Cognitive-Behavioral Treatment for Combat 
  33
Related Sleep Disturbances in Veterans with PTSD”, protocol number HM12565 as well as 
the Hunter Holmes McGuire Veterans Affairs Medical Center’s Institutional Review Board 
under the same title “Effects of a Cognitive-Behavioral Treatment for Combat-Related Sleep 
Disturbances in Veterans with PTSD”, ID number 01560. 
Study Site 
  The study took place at the mental health clinic of the Hunter Holmes McGuire 
Veterans Affairs Medical Center in Richmond, VA. 
Experimental Overview 
  Veterans enrolled in the mental health clinic and participating in the OEF/OIF 
Outreach Program at the McGuire VAMC were invited to participate in a randomized 
controlled trial comparing CBT-I to a waitlist control group. For the treatment group, the 
study involved baseline assessment followed by four individual sessions of CBT-I and a 
posttreatment assessment. For the control group, the study involved baseline assessment, a 
six-week waitlist period in which the participants were contacted weekly, follow-up 
assessment and then the option to participate in treatment. Follow-up assessments for those 
who participated in treatment occurred at six to nine months postintervention. 
 At baseline, participants who provided informed consent completed questionnaires 
assessing sleep quality and sleep quantity, insomnia severity, beliefs and attitudes about 
sleep, post-traumatic severity, nighttime symptoms of PTSD, mood and daytime functioning. 
At posttreatment and 6-9 month follow-up, participants were asked to complete a follow-up 
packet consisting of the same questionnaires administered at baseline. 
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Participants 
 Participants were recruited in person and by phone by the lead investigator, Skye 
Ochsner Margolies, M.A. from November 2009 to May 2010. Recruitment was conducted in 
several ways: The investigator was invited to present the study during the last ten minutes of 
ongoing group sessions focusing on PTSD (i.e. PTSD Boot Camp and Young Guns) and 
interested veterans were invited to speak with the investigator about the study. Therapists 
working in the PTSD Clinic, as well as those in the general Mental Health Service, also made 
referrals to the study, at which time veterans were either seen that day or contacted by phone. 
Finally, the OEF/OIF Outreach Program social worker provided the investigator with a list of 
veterans who fit PTSD diagnostic criteria for the study and these veterans were contacted, 
screened, and if eligible, invited to participate in the study. 
 Informed consent was obtained in the presence of John Lynch, PhD, as required by 
the McGuire VAMC’s IRB. Once informed consent was obtained, the participant was 
provided with a copy of the consent document and the original consent form was retained by 
the research team and filed in a locked drawer.  
 Inclusion Criteria. In order to be randomized to the study, participants needed to 
meet the following criteria: (a) be a veteran of either OEF and/or OIF (b) have a diagnosis of 
Posttraumatic Stress Disorder as determined by the intake conducted through the PTSD 
Clinic and/or the Mental Health Service Clinic (c) be currently experiencing symptoms of 
sleep disturbance which was determined by the investigator of the study who screened for 
current symptoms of sleep disturbance specifically defined as (1) at least three episodes of 
insomnia per week for at least six months (an episode is defined as taking at least 30 min to 
fall asleep, being awake for at least 60 min after falling asleep, or accumulating less than 6.5 
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hr of sleep per night) and (2) daytime consequences of insomnia, such as fatigue, irritability, 
or difficulty concentrating. This definition is based on typical research criteria (Rybarczyk et 
al., 2005; Perlman et al., 2008) and research diagnostic criteria as operationalized by a work 
group commissioned by the American Academy of Sleep Medicine (Edinger et al., 2004).  
  Exclusion Criteria.  Individuals were ineligible for study participation if they: (1) 
met criteria for current (within the last six months) history of alcohol or substance 
dependence or abuse, bipolar or any psychotic disorder, and severe, untreated major 
depression; (2) were previously diagnosed with sleep apnea that was not treated; (3) were 
diagnosed with a seizure disorder as recent research has shown that for certain patients 
(diagnosed with bipolar or seizure disorder) sleep deprivation is risky as it may facilitate a 
manic episode and lower the seizure threshold (Smith, Huang, & Manber, 2005).  
Exclusionary criteria were assessed both through electronic medical records as well as during 
an in-person screening with the investigator prior to consent. These exclusionary criteria 
were determined by using the standard in current research (Rybarczyk et al., 2005; Germain, 
Shear, & Buysse, 2007).  Participation was not restricted by age, gender, race/ethnicity, 
medication or other comorbidity. 
Study Procedures 
Baseline Assessment. During the initial session in which consent was obtained, 
veterans were informed that the study would involve a baseline assessment (approximately 
45 minutes) and a follow-up assessment. If participants had been randomized to the treatment 
group, they were told they would be participating in four sessions of CBT-I and that these 
sessions would occur weekly with a two-week break between the second and third session. 
For participants in the waitlist control group, they were informed that they would be 
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contacted weekly over the next six weeks, after which they would fill out follow-up 
questionnaires and then have the option of participating in CBT-I treatment.  Veterans in the 
waitlist control group filled out questionnaires before and after the six-week treatment time 
and were offered the CBT-I treatment once the initial phase was completed. 
 Measures at Baseline. Basic demographic information was obtained from the 
McGuire VAMC’s electronic medical record.  All measures were administered after 
participants consented to participate in the study and following the six-week treatment 
window. The following measures were administered:  
 Sleep Diaries were completed during the two-week baseline assessment period and 
for two weeks posttreatment after having filled out questionnaires.  The actigraph, which 
was only used by veterans who were initially randomized to the treatment group, was worn 
for one week during the two-week baseline assessment and posttreatment periods.  
 Sleep Diary. (see Appendix A) The Sleep Diary (Morin, 2003) is a self-report record 
that is completed by participants each morning for two weeks prior to treatment, during the 
six-week treatment phase, and for two weeks after completion of treatment. Diaries include 
information about patients’ bed and rising time, sleep-onset latency (SOL), frequency and 
total duration of awakenings (wake time after sleep-onset; WASO). Measures derived from 
diaries include total sleep time (TST), SOL, WASO, total wake time (TWT =SOL + WASO) 
and sleep efficiency (SE = [TST ÷ Time in Bed] x 100%) (Edinger et al., 2007). As a 
complement to this information, participants also rated their quality of sleep. 
 Actigraphy. Activity data was collected with an Actigraph recorder (Ambulatory 
Monitoring, Inc., Ardsley, New York).  This system is a wrist monitor that contains a 
piezoelectric linear accelerometer that records both intensity and frequency of movement.  
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Such movement was used to determine sleep disturbance and fragmentation throughout the 
night (Lichstein et al., 2006). Total sleep time and sleep efficiency were computed using the 
software analysis program that was provided with the device. Participants wore the Actigraph 
on the wrist of their non-dominant hand for one week. A 30-second epoch length was used 
for data collection as this allowed for sufficient sensitivity to make use of the analysis 
software for sleep scoring.  When the one-week assessment was completed, participants 
turned in the actigraph along with their sleep diaries and the data from the Actigraph was 
downloaded and stored in a PC at the McGuire VAMC. 
 PTSD Symptom Scale- Self Report (PSS-SR; Foa, Riggs, Dancu & Rothbaum, 1993). 
See Appendix B. The PSS is a self-report, 17-item measure reflecting the DSM-IV symptoms 
of PTSD. Symptom frequency is assessed by calculating symptoms endorsed in subscales (a) 
Re-experiencing (5 items), Avoidance (7 items) and Arousal (5 items). The PSS-SR has high 
internal consistency and good test-retest reliability (Foa et al., 1993). 
 Pittsburgh Sleep Quality Index (PSQI). See Appendix C. The PSQI (Buysse, 
Reynolds, Monk, Berman, & Kupfer, 1989) is a self-report 19-item measure designed to 
assess sleep quality during the past month. Seven domains of sleep difficulties are assessed 
by the PSQI: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, 
sleep disturbances, use of sleeping medication, and daytime dysfunction. Together, the sum 
of these scores for these domains yields one global score of overall sleep quality. Higher 
scores are a reflection of poorer sleep quality. The PSQI has a high test-retest reliability and 
good validity in particular for patients with primary insomnia (Backhaus. Junghanns, 
Broocks, Riemann, & Hogen, 2002) . Furthermore, in a recent consensus statement, it was 
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recommended that the PSQI be used in all treatment outcome studies as a means of 
standardizing insomnia research (Buysse, Ancoli-Israel, Edinger, Lichstein, & Morin, 2006). 
 Pittsburgh Sleep Quality Index Addendum for PTSD (PSQI-A). See Appendix D. The 
PSQI-A is an addendum to the PSQI and is designed to assess the frequency of disruptive 
nocturnal behavior (DNB), a hallmark symptom of PTSD. Specifically, participants rate the 
frequency of seven items that reflect DNB: general nervousness, memories or nightmares of 
traumatic experience, severe anxiety or panic not related to traumatic memories, bad dreams 
not related to traumatic memories, episodes of terror or screaming during sleep without fully 
awakening, and episodes of acting out dreams, such as kicking, punching, running or 
screaming (Germain, Hall, Krakow, Shear & Buysse, 2005). The PSQI-A has proven to be a 
reliable instrument with high internal consistency and good convergent validity with good 
sensitivity to change (Germain et al., 2005). 
 Insomnia Severity Index (ISI). See Appendix E. The ISI is a seven-item measure 
(Bastien, Vallieres & Morin, 2001) that yields a global score of sleep impairment. 
Participants rate sleep difficulty in terms of its severity, degree of interference with daily 
functioning, noticeability of such impairment to others, level of distress and overall 
satisfaction with sleep. This scale has good internal validity and appropriate test–retest 
reliability over a two-week interval. Scores vary between 1 and 5 (higher scores equal greater 
levels of impairment). 
 Dysfunctional Beliefs and Attitudes About Sleep Scale (DBAS). (See Appendix F). The 
DBAS (Morin, 1993) is a 30-item self-report scale designed to assess sleep-related beliefs 
and attitudes. The items measure various beliefs, attitudes, expectations, and attributions 
about sleep and insomnia. These cognitions reflect several conceptually derived themes such 
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as sleep requirement expectations, causal attributions and perceived consequences of 
insomnia, control and predictability of sleep, and beliefs about sleep-promoting practices. 
Items include a 3-inch visual analog scale, with strongly disagree and strongly agree 
descriptors at each end of the scale. Higher scores on the DBAS reflect more dysfunctional 
beliefs about sleep and misattributions of the consequences of insomnia.  The DBAS has 
reported good internal consistency and has demonstrated measurement sensitivity to 
cognitive-behavioral treatment (Espie, Inglis, Harvey & Tessier, 2000; Edinger et al., 2009). 
Subscale scores will be calculated by using the mean scores on the items that make up the 
DBAS-16. Subscales include: (1) expectations for sleep; (2) worry/helplessness about sleep; 
(3) consequences of insomnia; and (4) beliefs about the importance of medication for sleep. 
The DBAS-16 represents a more streamlined version of the DBAS that is now more 
commonly used in the literature (Morin, Vallieres & Ivers, 2007). The DBAS-16 has good 
reliability and higher internal consistency than the DBAS (Carney et al., 2010).  
 Insomnia Treatment Evaluation Questionnaire (ITEQ). (See Appendix G). The ITEQ 
was developed by Mimeault and Morin (1999) for measuring insomnia treatment plausibility. 
Using a 100-mm visual analog scale ranging from not at all to extremely, participants rate the 
following about the treatment: (a) if the rationale made sense, (b) how acceptable the 
treatment was for them, (c) suitability for their sleep problems, and (d) expected 
effectiveness for their sleep problems.  
 Patient Health Questionnaire (PHQ). (See Appendix H).The PHQ (Spitzer, Kroenke, 
Williams, et al., 1999) is a modified version of Prime-MD, which consisted of a patient 
questionnaire and a clinician evaluation guide. The PHQ is a combination of these two 
components in a three-page self-report measure. The PHQ assesses eight diagnoses, which 
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are divided into threshold diagnoses (major depressive disorder, panic disorder, bulimia 
nervosa) and subthreshold diagnoses (other depressive disorder, other anxiety disorder, 
alcohol abuse/dependence, binge eating disorder, somatoform disorder). The PHQ has 
diagnostic validity comparable to the original clinician administered instrument (Spitzer, 
Kroenke, Williams, et al., 1999). For the purposes of this study, only the depression subscale 
was analyzed due to a printing error in the questionnaires that were administered in the study. 
 The Profile of Mood States (POMS). (See Appendix I). The POMS (McNair, Lorr, & 
Droppleman, 1971) is a 65-item self-report measure of affective states for the past week. 
Patients are asked to rate each item using five levels of severity. Affective states are 
measured by six subscales tapping into the following dimensions: vigor, tension, depression, 
anger, fatigue, and confusion. It has good test–retest reliability, predictive construct, and 
concurrent validity (McNair et al., 1971). The POMS total mood disturbance score can be 
used as an overall indicator of distress. 
Intervention 
Cognitive Behavioral Therapy for Insomnia with Imagery Rehearsal Therapy. The 
intervention consisted of four, 60-minute individual sessions (Edinger et al, 2007; Morin, 
2003) largely based on Morin’s (2003) insomnia treatment program with the added 
component of IRT. Skye Ochsner Margolies (SOM), M.A. provided the treatment after being 
trained by Bruce Rybarczyk, PhD who is an expert in sleep medicine. John Lynch, Ph.D. was 
on site at the McGuire VA Medical Center as a supervisor. Additionally, the treatment 
provider (SOM) met on a regular basis with Dr. Rybarczyk at VCU to discuss treatment 
progress.  Sessions were conducted at the Hunter Holmes McGuire VA Medical Center 
during a six-week treatment period (there was a two week break between the second and 
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third session). The treatment arm closely followed Morin's (1993, 2003) insomnia treatment 
protocol with the addition of imagery rehearsal therapy components. The adaptation of IRT 
used in this study was based on the study conducted by Germain and colleagues (2007) in 
which CBT-I and IRT were combined in a one-session treatment for PTSD-related sleep 
disturbances in a population of seven adult victims of violent crimes. In particular, this 
modified and abbreviated version of IRT specifically focused on the rationale and application 
of imagery rescripting.  Each session in this study included an educational component about 
sleep and behaviors or cognitions that promote or interfere with sleep quality, a review of the 
patient's sleep log and a discussion aimed at resolving problems the patient experienced in 
implementing the techniques (Rybarczyk et al., 2005).  
 Following a brief review on the basics of sleep and sleep architecture, the therapist 
reviewed the sleep diary with the participant and explained the rationale for sleep restriction. 
During this first session, a new sleep schedule was derived based on how many hours the 
patient was reportedly asleep, in contrast to how much time the participant was spending in 
bed. The veteran chose a wake-up time that fit with his or her schedule and from that anchor, 
a bedtime was established. If time permitted, Imagery Rehearsal Therapy (IRT) was also 
introduced in the first session to help patients restructure frequent nightmares that contribute 
to their insomnia. If there was not enough time during this first session, IRT was briefly 
introduced in session one and then more comprehensively discussed during the second 
session. In session, veterans were asked to select a nightmare they have had and to write it 
down in the first person. They were then asked to rewrite the nightmare in any way they wish 
so that the content is neither unpleasant nor distressing. They were then given time for an 
imaginal rehearsal of the new dream. Participants were told to practice this rescripted dream 
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at home at least three times a day for a minimum of five minutes (Germain et al., 2007). It 
should be noted that the investigator experienced difficulty having many of the participants 
engage in this portion of treatment. This issue will be addressed further in the Discussion 
section.  
 The behavioral component of the intervention included sleep-scheduling --combining 
both stimulus control (Bootzin & Epstein, 2000) and sleep restriction therapy (Spielman, 
Saskin & Thorpy, 1987) -- and sleep hygiene (Morin, 2004). These concepts were introduced 
in the first and second sessions and were reviewed throughout treatment. Sleep scheduling 
was designed to (1) help patients strengthen their associations between the bed/bedroom and 
sleep and (2) establish a consistent sleep-wake schedule. Participants were instructed to (a) 
go to bed only when sleepy, (b) get out of bed when unable to sleep and lie awake in bed no 
longer then fifteen minutes, (c) use the bed for sleep only (reading, television, and talking on 
the phone should be done in another room; sex is the only activity that is allowed in the bed), 
(d) wake up at the same time every morning and (e) avoid daytime naps. 
 Sleep hygiene education was used to introduce the patient to general guidelines about 
health practices and environmental factors that may either facilitate or interfere with sleep. 
Habits such as exercise, diet, substance use, light, noise, and temperature were a focus 
(Morin, 2006). The cognitive aspect of this CBT-I treatment was designed to change patients' 
"beliefs, expectations, appraisals, and attributions" (Morin, 2003) about insomnia. The 
cognitive component of the proposed treatment included cognitive restructuring and IRT 
(mentioned above). The main targets of cognitive restructuring were (a) unrealistic 
expectations about sleep needs and daytime functioning, (b) misconceptions and false 
attributions about the causes of insomnia, (c) distorted perceptions of insomnia’s 
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consequences, and (d) faulty beliefs about sleep-promoting practices (Morin, 2003). In 
session, the therapist guided the patient in identifying dysfunctional sleep cognitions, 
challenging their validity and reframing these cognitions into more adaptive beliefs. 
Cognitive restructuring was performed throughout treatment.  
 Waitlist Control Group. Veterans in the waitlist control group completed baseline 
sleep diaries and questionnaires. During the six-week waitlist period, participants were 
contacted on a weekly basis. After six weeks, veterans completed another set of sleep diaries 
and questionnaires. At this point, they were offered the CBT-I treatment. 
Follow-Up Assessments. 
 Two-Week Follow-Up.  Two weeks after the fourth session, participants were asked 
to complete a follow-up packet, including each questionnaire that was administered prior to 
treatment. During those two weeks, all participants still completed sleep diaries and veterans 
in the treatment condition wore the actigraph for one week. Both the sleep diaries and the 
actigraph were handed in at this follow-up assessment. For the waitlist control group, 
participants received this same packet of questionnaires including two weeks of sleep diaries, 
which they completed and returned to the investigator after two weeks. Assessments were 
administered by the investigator and for those individuals who participated in treatment, they 
were reminded that the investigator would be in touch with them to complete a follow-up 
packet of assessments equivalent to the ones they had just completed. 
 Six to Nine Month Follow-Up.  All participants who completed treatment were 
mailed a follow-up packet of questionnaires and sleep diaries. 
Dependent Measures 
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 Dependent measures included scores related to the following domains and derived 
from the following measures (1) Sleep: sleep diaries, ISI, PSQI, DBAS and Actigraph; (2) 
PTSD Symptom Severity: PTSD-SR and PSQI-A; and (3) Mood and overall Quality of Life: 
POMS and PHQ.  
 Specifically, sleep was measured by examining sleep quality (sleep efficiency, sleep 
onset latency, wake after sleep onset –WASO) and sleep quantity (total sleep time), as 
recorded in participant sleep diaries. Averages over two weeks of sleep diary recordings were 
calculated to derive mean scores for sleep onset latency, wake after sleep onset and total 
sleep time. A ratio of mean total sleep time to mean time in bed was calculated to determine 
a percentage value for sleep efficiency: (SE = [TST ÷ Time in Bed] x 100%). Actigraphy 
recordings also provided data for sleep variables measuring sleep quality and sleep quantity 
for the treatment condition. Further related to sleep, total scores were derived from the ISI, 
PSQI and the DBAS, measures that assess insomnia severity, sleep quality and beliefs about 
sleep, respectively. On the ISI, higher scores are indicative of more severe insomnia. For the 
PSQI, high scores indicate poor sleep quality and on the DBAS, high scores reflect 
dysfunctional thoughts about sleep. PTSD symptom severity was measured using the total 
sum of scores of items assessing re-experiencing, arousal, and avoidance symptoms from the 
PSS-SR.  Nighttime sleep disturbances related to PTSD were measured using the total sum of 
scores from the PSQI-A. Mood was evaluated by using total sums of the depression subscale 
of the PHQ. Distress was measured using the total sum of scores from the POMS while 
component scores derived from the POMS were also used to examine daytime functioning: 
tension, depression, vigor, anger, confusion and fatigue.  
Data Analysis 
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Descriptive statistics were computed to examine subject characteristics. T-test and 
chi-square analyses were run to examine sample representativeness and potential 
generalizability. These analyses also examined whether there were significant differences 
between treatment conditions at baseline. T-test and chi-squares further examined whether 
there were group differences on demographic variables.  
Hypothesis #1. The first hypothesis predicted that, relative to the waitlist-control 
condition, individuals assigned to the treatment condition would show increased sleep 
quantity (total sleep time) and quality (decreased sleep onset latency, decreased wake after 
sleep onset, and increased sleep efficiency). It was also posited that relative to the veterans in 
the waitlist control condition, veterans participating in treatment would show a decrease in 
insomnia severity (ISI) and sleep difficulties (PSQI) and demonstrate more realistic 
cognitions related to sleep (DBAS). (This analysis was also included to serve as a 
manipulation check on the cognitive component of the treatment.) Furthermore, it was 
predicted that these treatment gains would be maintained at the follow-up assessment.  
Intent to treat analysis was conducted to test Hypothesis #1. Specifically, baseline 
responses were carried over to posttreatment responses for participants who did not complete 
treatment or complete posttreatment questionnaires. Short-term effects were tested using a 
Condition (treatment condition versus waitlist control condition) x Time (baseline and 
posttreatment) repeated measures multivariate analysis of covariance (MANCOVA) for 
subjective measures of sleep recorded in the sleep diary (sleep efficiency, wake after sleep 
onset- WASO, sleep onset latency and total sleep time). Condition x Time repeated measures 
ANOVAS were used to examine self-reported feelings about sleep as measured by the ISI, 
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the PSQI and the DBAS.  Interaction effects were examined with post-hoc analyses, 
specifically repeated measures ANOVAS and independent samples t-tests.  
Longer-term effects (measured at six to nine month follow-up) were examined using 
repeated-measures ANOVA (treatment condition at baseline, posttreatment, and 6-9 month 
follow-up) in order to examine maintenance of treatment gains (sleep diary variables and 
sleep related questionnaires) for all veterans who participated in treatment. 
Hypothesis #2. The second hypothesis predicted that, relative to the waitlist-control 
condition, individuals assigned to the treatment condition would show reductions in PTSD 
severity and improvements in mood and daytime functioning.  
A Condition (treatment condition versus waitlist control condition) x Time (baseline 
versus posttreatment) repeated measures ANOVA was conducted in order to examine 
whether veterans in the treatment condition experienced reductions in PTSD severity, 
improved mood, and better daytime functioning compared to individuals in the waitlist 
control condition. A Condition x Time repeated measures ANCOVA was conducted in order 
to examine PTSD related nighttime disturbances. Baseline scores on the PSQI-A were used 
as a covariate to control for baseline differences between the treatment and control group. 
Interaction effects and post-hoc analyses were examined.  
Hypothesis #3. The third hypothesis predicted that veterans in the treatment 
condition would show increased sleep quantity (total sleep time) and quality (sleep onset 
latency, wake after sleep onset, and sleep efficiency) as recorded by actigraphy. Actigraphy-
measured effects were tested by using a repeated measures analysis of variance (ANOVA) to 
look at objective sleep efficiency, WASO, sleep onset latency, and total sleep time over time 
(baseline to posttreatment).  
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Results 
 
Demographics 
 Table 2 summarizes demographic characteristics for the entire sample and separately 
for the treatment condition and waitlist control conditions. These data were obtained from the 
McGuire VAMC’s electronic medical record. Overall, veterans randomized to the study were 
in their late-30’s (mean = 37.7 years, SD=9.1), 90% were men and over 60% identified as 
Black. Many of the veterans were participating in PTSD treatment while also participating in 
this study. Overall, 65% of veterans were involved in some form of treatment for PTSD 
(group and/or individual).  Group treatment involved PTSD support groups focusing 
specifically on OEF/OIF veterans. Individual treatment involved evidenced based approaches 
including Prolonged Exposure Therapy and Cognitive Processing Therapy. Participation in 
group therapy included 45% of the total sample while participation in individual treatment 
for PTSD included 42.5% of the total sample. Comparisons for veterans randomized to the 
treatment condition and the waitlist control condition were made using independent t-tests for 
continuous measures and chi-square analyses for categorical measures. No group differences 
were observed. 
Table 2. 
Participant Characteristics: Treatment Condition (n =20) and Waitlist Control (n =20)  
 Treatment Group Waitlist Control Total Sample 
 % or M (SD) % or M (SD) % or M (SD) 
Age (years) 
 
36.43 (9.3) 
range: 24-54 
39.11 (8.9) 
range: 21-52 
37.7 (9.1) 
range: 21-54 
Sex    
% Male  90% 90% 90% 
% Female 10% 10% 10% 
    
Race      
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% White 40% 40% 40% 
% Black 60% 60% 60% 
    
PTSD Treatment    
Group Treatment 50% 40% 45% 
Individual Treatment 40% 45% 42.5% 
Group and Individual 
Treatment 
65% 65% 65% 
 
Data Screening and Manipulation Checks 
Outliers and Tests of Normality. Frequency distributions and univariate statistics 
were examined for evidence of non-normality and outliers. Kolmogorov-Smirnov and 
Shapiro-Wilk statistics and visual inspection of the data plotted on histograms were used to 
test for normality of the data and to detect outliers. Over the course of two assessments 
(baseline and posttreatment assessment) outliers were detected for three of the sleep diary 
variables, including: n = 1 on sleep efficiency at baseline (z = 3.73), n = 1 for sleep onset 
latency at baseline (z = 4.8), and n = 1 (z = 4.98) at posttreatment; n = 2 for wake after sleep 
onset at baseline (z = 2.98 and z = 3.2) and n = 1 at posttreatment (z = 3.55). Homogeneity of 
variance of the dependent variables was evaluated to ensure assumptions of the statistical 
method were not violated. Outliers for any raw scores were changed to represent two 
standard deviations above the mean. 
Success of Randomization. Out of n = 40 participants who completed 
randomization, n = 20 (50%) were randomized to the treatment condition and n = 20 (50%) 
were randomized to the waitlist control condition.  
 Analyses were run to examine whether there were significant baseline differences 
between veterans randomized to experimental and control groups (see Table 3 for means and 
standard deviations). No significant differences were found for most sleep diary variables 
  49
(sleep onset latency, WASO, and total sleep time), baseline beliefs about sleep (DBAS), 
severity of insomnia (as rated on the ISI), global sleep quality (as measured by the PSQI), 
PTSD severity (PSS-SR), overall distress as well of reported depression, tension, vigor, 
anger, fatigue or confusion as measured by the POMS and depression as measured by the 
depression subscale of the PHQ. Veterans in the treatment condition also reported less 
frequent nighttime PTSD symptoms (as measured by the PSQI-A) than those in the waitlist 
control condition (M = 9.7, [SD=3.9] versus M = 11.4, [SD = 6.4], respectively), t (34) = 1.2, 
p < .05.   
Table 3. 
Baseline Comparisons: Treatment Condition (n = 18) and Waitlist Condition (n = 16) 
 Treatment Group Waitlist Control Total Sample 
 % or M (SD) % or M (SD) % or M (SD) 
Sleep Efficiency 71.5 % (11.5) 76.6% (5.2)  73.9 % (9.3) 
range: 51 – 90% 
Sleep Onset Latency 
(minutes) 
33.4 (20.4) 28.7 (15.6) 30.4 (16.1) 
range: 7 - 63 
Wake After Sleep 
Onset 
36.9 (23.6) 40.9 (20.2) 38.8 (21.8) 
range: 9 - 78 
Total Sleep Time 
(minutes) 
282.4 (93.7) 333.6 (112.4) 306.5 (104.6) 
range: 135 - 519 
Insomnia Severity 
(ISI) 
19.85 (3.8) 21.4 (3.9) 20.6 (3.9) 
range: 13 - 28 
Sleep Quality (PSQI) 14.75 (2.9) 14.82 (3.5) 14.78 (3.2) 
range: 8 - 20 
Beliefs about Sleep 
(DBAS) 
54.50 (10.6) 58.18 (12.3) 49.2 (11.4) 
range: 20 - 75 
PTSD Symptom 
Severity (PSS-SR) 
41.23 (13.9) 44.5 (13.4) 42.68 (13.6) 
range: 13 - 72 
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Nighttime PTSD 
symptoms (PSQI-
A)* 
 
9.7 (3.9) 11.38 (13.4) 10.44 (5.2) 
range: 20 - 21 
Overall Distress 
(POMS) 
117 (28.5) 118.44 (38.5) 117.68 (33) 
range:  49 - 181 
Depression (POMS) 22.89 (12.8) 22.75 (15.1) 22.82 (13.8) 
range: 1 - 54 
Tension (POMS) 20.39 (7.5) 21.56 (8.5) 20.9 (7.9) 
range: 8 - 36 
Vigor (POMS) 10.94 (5.6) 11.19 (5.5) 11.1 (5.5) 
range: 1 - 24 
Anger (POMS) 22.56 (9.6) 22.31 (12) 22.44 (10.6) 
range: 2 - 39 
Confusion (POMS) 14.5 (4.3) 14 (5.6) 14.26 (4.9) 
range: 4 - 22 
Fatigue (POMS) 16 (5.1) 17.81 (6.5) 16.85  (5.8) 
range: 1 - 24 
Depression (PHQ-9) 13.31 (3.8) 13.18 (5.9) 13.26 (4.8) 
range: 4 -25 
* = Significant baseline differences between veterans randomized to experimental and 
control groups 
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Figure 1. Flow chart of participants through study. 
 
 
Attrition. As depicted in Figure 1, rates of compliance with the treatment and waitlist 
condition varied with 80% of participants in the treatment condition (n =16) completing 
treatment while 70% of participants remained in the waitlist control condition (n =14) from 
baseline to six-week follow-up. Chi-square analyses reveal no significant differences in rates 
of attrition between groups. Chi-square analyses and t-tests comparing completers and 
noncompleters on demographics and baseline data revealed no significant differences either. 
Of the veterans in the treatment condition, two participants dropped out shortly after 
consenting and before completing baseline questionnaires and two dropped out after two 
Randomized 
(n = 40) 
Randomized to 
Treatment Group 
(n = 20) 
Randomized to 
Wait List Group 
(n = 20) 
Treatment Sessions Completed 
One Session:  (n = 18) 
Two Sessions:  (n = 18) 
Three Sessions: (n = 16) 
Four Sessions:  (n = 16) 
Completed treatment measures: (n =16) Treatment Sessions Completed: 
One Session: (n = 8) 
Two Sessions:  (n = 7) 
Three Sessions: (n = 6) 
Four Sessions: (n = 5) 
Completed treatment measures: (n=5) 
Completed 6-9 Month Post-Intervention:  
(n = 2) 
Drop Out after Consent:   (n = 3) 
Drop Out During Wait List:  (n = 3) 
Remained in Waitlist Condition:  (n = 14) 
 
Crossed Over to Treatment:  (n = 8) 
Completed 6-9 Month Post-Intervention: 
(n = 7) 
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sessions of CBT-I. Reasons for drop out included employment, arrest, and lost to follow-up. 
Of the veterans in the waitlist control condition, two participants consented to participate but 
did not show up for collection of baseline data and four participants completed baseline 
questionnaires but were not available for follow-up. (Two participants completed some of the 
follow-up questionnaires but not all.) Of the eight wait-list control participants who crossed 
over to treatment, five participants completed treatment. The three participants who dropped 
out of treatment after having crossed over did so for reasons including pregnancy, a 
motorcycle accident and lost to follow-up. 
Treatment Plausibility.  The ITEQ, administered to participants at the baseline 
assessment, was used to assess participants’ perception of the insomnia treatment after being 
introduced to the general rationale and concepts during the consenting process. Both groups 
had total mean scores indicating that overall they found the treatment to be moderately 
plausible (maximum rating = 100) for the total score (CBT-I = 71, waitlist = 63). On the first 
two items, veterans from both treatment conditions endorsed high acceptability of the 
treatment: treatment credibility (CBT-I = 82, waitlist = 77) and treatment acceptability (CBT-
I = 73, waitlist = 64).  On the last two ITEQ items, participants’ scores demonstrated 
moderate acceptability: appropriateness for their sleep difficulties (CBT-I = 67, waitlist = 57) 
and their expectation for how effective the treatment was going to be for their sleep problem 
(CBT-I = 60, waitlist = 55). There were no significant differences between groups for the 
total ITEQ score or for any of the individual ITEQ items. 
Hypothesis #1 
The first hypothesis stated that veterans in the treatment condition would show 
treatment gains on sleep diary variables and sleep-related questionnaires relative to veterans 
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in the waitlist control condition. An initial intent to treat analysis was conducted for primary 
sleep variables. 
Sleep Diary Variables. A repeated-measures MANOVA was conducted to assess the 
overall Condition x Time interaction of sleep diary variables (sleep efficiency, sleep onset 
latency, total sleep time and wake after sleep onset). For those participants who failed to 
complete sleep diaries at posttreatment, their baseline response was used as their 
posttreatment response. Consistent with the first hypothesis, the analyses found a significant 
Condition x Time interaction across the four sleep variables with a large effect size, F (4,29) 
= 5.4, p = .002, ηp2  = .428.  
Univariate analyses produced significant Condition x Time interactions for the 
following sleep variables: sleep efficiency F(1,32) = 23.08, p < .001, ηp2  = .419 (see Figure 
2); sleep onset latency F(1,32) =15.23, p < .001, ηp2  = .322 (see Figure 3); and WASO 
F(1,32) = 7.43, p = .01, ηp2  = .188 (see Figure 4). The effect for Total Sleep Time was not 
significant, F(1,32) = 3.31, , p = .08. ηp2  = .094. (See Table 4 for mean scores) although 
trended in the anticipated direction. The effect size for all significant sleep diary variables 
fell in the large range. 
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Figure 2. Sleep efficiency at pretreatment and posttreatment for the two conditions 
(treatment condition [CBT-I] compared with waitlist control condition). 
* Indicates the significant difference between CBT-I and Waitlist conditions at posttreatment. 
** Indicates the significant pretreatment to posttreatment difference for each condition. 
 
  
Figure 3. Sleep onset latency at pretreatment and posttreatment for the two conditions 
(treatment condition [CBT-I] compared with waitlist control condition). 
* Indicates the significant difference between CBT-I and Waitlist conditions at posttreatment. 
** Indicates the significant pretreatment to posttreatment difference for each condition. 
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Figure 4. Wake after sleep onset at pretreatment and posttreatment for the two conditions 
(treatment condition [CBT-I] compared with waitlist control condition). 
* Indicates the significant difference between CBT-I and Waitlist conditions at posttreatment. 
** Indicates the significant pretreatment to posttreatment difference for each condition. 
 
As can be seen in Table 17 (Appendix J), the treatment group demonstrated 
significantly improved sleep efficiency, F(1,17) = 30.17, p < .001, a significant decrease in 
sleep onset latency F(1,17) = 16.23, p = .001,  and significantly decreased wake after sleep 
onset F(1,17) = 15.82, p = .001. The waitlist group did not demonstrate significant change on 
any sleep related variables.  Although the Total Sleep Time analysis did not result in a 
significant Condition x Time interaction, the treatment group showed a marginal trend 
toward increased sleep, F (1, 17) = 3.6, p = .08.  All nonsignificant p’s > .11. 
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Table 4.  
Mean (and standard deviation) of CBT-I on Sleep Diary Variables: Treatment Condition 
(n=18) and Waitlist Condition (n = 16) 
 Baseline 
M (SD) 
Post-Treatment 
M (SD) 
Effect 
Size 
 
CBT-I Waitlist 
 

CBT-I Waitlist 
 

Sleep Efficiency 71.5 % (11.6) 76.6 % (5.2) 
 
86.5 % (6.8) c, ***  75.7 % (9.0) 
 
.399 
Sleep Latency 
(minutes)  
 
33.4 (20.4) 28.7 (15.6) 
 
15.3 (9.4) c, **  32.8 (24.1) a 
 
.27 
Total Sleep Time 
(minutes) 
 
282.4(93.7) 333.63(112.4) 
 
311.7 (98) 327.4 (98.5) 
 
.049 
Wake After Sleep 
Onset (minutes) 
 
36.9 (23.6) 40.9 (20.2) 
 
18.4 (13.8) c, ** 40.0 (23.4) 
 
.126 
a
 p < .05; b p < .01; c p < .001 (letters indicate that CBT-I or Waitlist condition was 
significantly different at posttreatment compared to that condition’s baseline value) 
*p < .05; **p < .01; *** p < .001 (asterisks indicate that CBT-I and Waitlist conditions were 
significantly different at posttreatment.)  
 
 Sleep Questionnaires.  See Table 5 for sleep questionnaire means by group.  Similar 
treatment effects were observed for severity of insomnia as measured by the Insomnia 
Severity Index (ISI). In particular, using intent to treat analyses, a significant Condition x 
Time interaction was found for severity of insomnia corresponding to a large effect size, 
F(1,35) = 16.24, p < .001, ηp2 = .317 (see Figure 5). The decrease in insomnia severity 
reported by veterans in the treatment condition revealed an improvement from moderately 
severe insomnia to sub-threshold insomnia F(1,19) = 22.41, p < .001, ηp2 = .541. Veterans in 
the waitlist control condition showed no significant changes over time and remained in the 
moderately severe insomnia category. 
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Clinically significant improvements on the ISI were measured by using the criterion 
for normal sleep (No clinically significant insomnia = score of 7 or below; subthreshold 
insomnia = score of 8-14). At posttreatment of the participants who completed posttreatment 
questionnaires, three in the treatment condition remitted from insomnia (3/15 or 20%) and 
seven participants were insomnia responders (8/15 or 53.3%). Only one participant in the 
waitlist condition (1/12 or 8.3%) remitted from insomnia.  
 
Figure 5. Insomnia severity (ISI) at pretreatment and posttreatment for the two conditions 
(treatment condition [CBT-I] compared with waitlist control condition). 
* Indicates the significant difference between CBT-I and Waitlist conditions at posttreatment. 
** Indicates the significant pretreatment to posttreatment difference for each condition. 
  
 On a measure of overall sleep quality (PSQI global sleep score), analyses revealed a 
significant Condition x Time interaction with a large effect size, F(1,35) = 25.28, p < .001, 
ηp2 = .419 (see Figure 6). From baseline to posttreatment, individuals in the treatment 
condition reported overall better sleep quality and a decrease in sleep difficulties (as 
measured by a decrease in the global score of the PSQI), F(1,19) = 27.58, p < .001, ηp2 =  
.592, while waitlist condition individuals showed no significant changes from baseline to 
posttreatment. 
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Recommendations for using the PSQI clinically and in research suggest a cutoff score 
of 5 (a lower score indicates fewer general sleep disturbances) (Buysee et al., 2006). At 
posttreatment, of the participants who completed posttreatment questionnaires, three in the 
treatment condition reported normal sleep based on the PSQI criterion (3/15 or 20%) while 
no veterans in the waitlist group achieved normal sleep at posttreatment.  
 
 
Figure 6. Overall sleep quality (PSQI) at pretreatment and posttreatment for the two 
conditions (treatment condition [CBT-I] compared with waitlist control condition). 
* Indicates the significant difference between CBT-I and Waitlist conditions at posttreatment. 
** Indicates the significant pretreatment to posttreatment difference for each condition. 
 
 On a measure assessing beliefs and attitudes about sleep (DBAS), intent to treat 
analyses revealed treatment effects trending in the expected direction, F (1, 34) = 2.6, p = 
.116, ηp2  = .071. As can be seen in Table 5, veterans who participated in treatment reported 
more functional beliefs about sleep with treatment whereas waitlist counterparts reported 
slightly more dysfunctional thinking about sleep. 
These data were also analyzed using the more streamlined version of this instrument, 
the DBAS-16 (Morin, Vallieres, & Ivers, 2007). This abbreviated version includes four 
subscales. Analyses of the DBAS-16 items revealed treatment effects also trending in the 
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expected direction, F (1, 34) = 3.42, p = .073, ηp2  = .091 with a large effect size (see Figure 
7). Follow-up analyses examining the individual subscales demonstrated a significant 
Condition x Time interaction for the medication subscale F (1,33) = 7.72, p = .009, ηp2  = 
.189, suggesting that treatment had a significant impact on participant beliefs about the need 
for medication to achieve better sleep. Veterans in the treatment group showed a trend in the 
expected direction suggesting that cognitive-behavioral treatment for insomnia is associated 
with modified beliefs about the role of medication in sleep. Treatment did not significantly 
affect participants’ expectations for sleep, worry about sleep or their beliefs about the 
consequences of insomnia, the three other DBAS-16 subscales. 
 
Figure 7. Beliefs about sleep (DBAS-16) at pretreatment and posttreatment for the two 
conditions (treatment condition [CBT-I] compared with waitlist control condition). 
* Indicates the significant difference between CBT-I and Waitlist conditions at posttreatment. 
** Indicates the significant pretreatment to posttreatment difference for each condition. 
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Table 5.  
Mean (and standard deviation) of Subjective Measures of Sleep: Treatment Condition (n=20) 
and Waitlist Condition (n = 17) 
 Baseline 
M (SD) 
Post-Treatment 
M (SD) 
Effect 
Size 
 
CBT-I Waitlist 
 

CBT-I Waitlist 
 

Insomnia Severity (ISI) 19.9 (3.8) 21.4 (3.9) 
 
14.4(5.9)c, *** 21.4 (4.3) 
 
.317 A 14.8 (2.9) 14.8 (3.4) 
 
10.8 (4.2) c, *** 15.5 (3.3) 
 
.419  54.50 (10.6) 58.18 (12.3)  48.1 (11.7)a, ** 58.18 (12.3) 
 
.091 
Note. ISI = Insomnia Severity Index; PSQI = Pittsburgh Sleep Quality Index; DBAS = 
Dysfunctional Beliefs and Attitudes about Sleep 
A  Lower ratings indicate better sleep 
a
 p < .05; b p < .01; c p < .001 (letters indicate that CBT-I or Waitlist condition was 
significantly different at posttreatment compared to that condition’s baseline value) 
*p < .05; **p < .01; *** p < .001 (asterisks indicate that CBT-I and Waitlist conditions were 
significantly different at posttreatment.)  
 
Hypothesis #2.  
The second hypothesis stated that as a result of treatment, veterans in the treatment 
condition would report a decrease in PTSD symptom severity and an improvement in 
daytime functioning. Mean baseline and posttreatment scores are available in Tables 8 and 9. 
Because of the significant results on measures of sleep, intent to treat analysis was not used 
to test Hypotheses #2 and #3. Rather, participants who failed to complete questionnaires at 
baseline or posttreatment were not included in these analyses. 
 PTSD Severity. Consistent with hypotheses, the treatment group and waitlist group 
reported significantly different trends in PTSD severity from baseline to posttreatment, 
Condition x Time F(1, 25) =16.71, p < .001, ηp2 = .401 (see Figure 8) with a large effect size. 
Means are reported in Table 8. Compared to pretreatment, veterans in the treatment condition 
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reported a significant decrease in PTSD symptom severity at posttreatment, F(1,14) = 12.39, 
p < .01, whereas veterans in the waitlist control condition showed a significant increase in 
PTSD symptom severity from pre- to posttreatment, F(1,11) = 5.58, p < .05.  
 
 
 
Figure 8. PTSD Symptom Severity at pretreatment and posttreatment for the two conditions 
(treatment condition [CBT-I] compared with waitlist control condition). 
* Indicates the significant difference between CBT-I and Waitlist conditions at posttreatment. 
** Indicates the significant pretreatment to posttreatment difference for each condition.  
                                                                        
Follow-up analyses looked at whether participation in PTSD treatment (individual or 
group) changed the impact of the intervention on PTSD symptom presentation. A 2 (Group) 
x 2 (current PTSD treatment/no current PTSD treatment) x 2 (pre-post treatment) repeated 
measures ANOVA was conducted and demonstrated that the significant Condition x Time 
interaction was maintained F(1,23) = 13.45, p = .001, ηp2 = .369. As can be seen in Table 6, 
Veterans who received both CBT-I and PTSD treatment as usual showed reduced PTSD 
severity from baseline to posttreatment while their waitlist counterparts showed increased 
PTSD severity over time. Furthermore, veterans who participated in CBT-I but were not 
involved in VA delivered PTSD treatment also demonstrated reduced PTSD severity from 
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pre to posttreatment whereas the one veteran receiving neither CBT-I nor PTSD treatment 
reported an increase in PTSD symptom severity. These findings suggest that participation in 
CBT-I could have an additive effect to traditional PTSD treatment. 
Table 6. 
Mean (and standard deviation) of CBT-I and PTSD Treatment on PTSD Severity   
 Baseline PostTreatment 
 CBT-I Waitlist 
 
CBT-I Waitlist 
 
In PTSD Treatmenta 
 
42 (15.9) 39.82 (11.9) 
 
36.55 (13.8) 45 (6.8) 
 
Not in PTSD Treatmentb 41.25 (9.7) 40 
 
25 (10.6) 70 
 
a
 Eleven veterans in the treatment condition and eleven veterans in the waitlist control 
condition were participating in VA PTSD treatment. 
b
 Four veterans in the treatment group did participate in PTSD treatment while one veteran in 
the waitlist control was not in PTSD treatment. 
 
 As can be seen in Figure 9, a repeated measures ANCOVA revealed significant 
Condition x Time interaction for nighttime symptoms of PTSD as measured by the PSQI-A, 
F(1,23) = 7.30, p =.01, ηp2 = .241. The baseline Total Score of the PSQI-A was used as a 
covariate. Effect size for this analysis was considered large. Participants in the treatment 
condition reported fewer nighttime related PTSD symptoms F(1,14) = 6.62, p = .02 while 
waitlist counterparts showed no significant changes over time. 
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Figure 9. PTSD related nighttime disturbances pretreatment and posttreatment for the two 
conditions (treatment condition [CBT-I] compared with waitlist control condition). 
* Indicates the significant difference between CBT-I and Waitlist conditions at posttreatment. 
** Indicates the significant pretreatment to posttreatment difference for each condition. 
 
The PSQI-A contains a question about nightmare frequency per week. It was 
hypothesized that as a result of CBT-I, veterans in the treatment condition would report a 
decrease in nightmare frequency. Because an independent measure of nightmare frequency 
was not included in this study, the response to one of the items of the PSQI-A (“1c. During 
the past month, how often have you had trouble sleeping because you had memories or 
nightmares of a traumatic experience?”) was used to explore the effect of treatment on 
nightmare frequency. Table 7 details the frequency with which participants reported having 
nightmares at baseline and posttreatment. Analysis of this item reveals a significant 
Condition x Time interaction, F(1,24) = 5.24, p < .05, ηp2 = .179. Further analyses 
demonstrated that participants trended in the anticipated direction such that veterans in the 
waitlist control condition reported more nightmares over time (p = .05). Veterans in the 
treatment condition reported a nonsignificant decrease in trauma related nightmare frequency 
(p = .21).   
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Table 7.  
Frequency of nightmares reported on Question 1C, PSQI-A from baseline to posttreatment. 
 Baseline PostTreatment 
 CBT-I Waitlist 
 
CBT-I Waitlist 
 
Not during the past month 
 
10% 18.75% 
 
26.66% 8.33% 
 
Less than once a week 
 
20% 6.25% 
 
13.33% 0% 
 
One to two times a week 
 
40% 18.75% 
 
26.66% 33.33% 
 
Three times or more a week 30% 56.25% 
 
33.33% 58.33% 
 
 
Table 8.  
Mean (and standard deviation) of CBT-I on PTSD Severity: Treatment Condition (n =15), 
Waitlist Condition (n = 12)A.      

 

               
A: n=11 for waitlist condition’s response to PSQI-A 
a
 p < .05; b p < .01; c p < .001 (letters indicate that CBT-I or Waitlist condition was 
significantly different at posttreatment compared to that condition’s baseline value) 
*p < .05; **p < .01; *** p < .001 (asterisks indicate that CBT-I and Waitlist conditions were 
significantly different at posttreatment.)  
 
Mood Symptoms and Daytime Functioning. Mood and daytime functioning was 
measured using the POMS and the PHQ (see Table 9 for pretreatment and posttreatment 
means). With respect to overall mood symptoms and daytime functioning, a significant 
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Condition x Time interaction with a large effect size was found when looking at overall 
distress as measured by the total score of the POMS, F(1,24) = 8, p < .01, ηp2 = .25, (see 
Figure 9). Specifically, treatment condition participants reported a decrease in overall distress 
at posttreatment F(1,13) = 6.12, p < .05, ηp2 =  .32, while waitlist control participants showed 
no significant changes in level of distress over time. 
 
Figure 10.  Overall distress pretreatment and posttreatment for the two conditions (treatment 
condition [CBT-I] compared with waitlist control condition). 
* Indicates the significant difference between CBT-I and Waitlist conditions at posttreatment. 
** Indicates the significant pretreatment to posttreatment difference for each condition. 
 
Significant interactions of Condition x Time were found for the POMS mood and 
daytime functioning domains of depression F (1,24)= 6.5, p < .05; tension F (1,24) = 5.7, p < 
.05; anger F(1,24) = 5.3, p < .05; confusion F(1,24) = 9.4, p = .005; and fatigue F(1,24) = 
5.2, p < .05. No significant difference was observed for the component score of vigor (See 
Table 9 for mean scores and Table 22 in Appendix J for ANOVAs). 
Participants in the treatment condition reported decreased tension F(1,13,) = 6.53, p 
=.02, anger F(1,13) = 4.94, p < .05, confusion F(1,13)=7.8, p = .01, and fatigue F(1,13) = 
0
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5.9, p < .05 while participants in the waitlist condition showed no significant changes over 
time for any of these component scores. Follow-up to the significant Condition x Time 
interaction for depression revealed that mean scores trended in opposite directions for each 
group such that veterans in the treatment group indicated less depression posttreatment while 
their waitlist counterparts reported greater levels of depression posttreatment (p’s < .10). 
Table 23 in Appendix J lists all ANOVAs. 
 As can be seen in Figure 11, veterans in the treatment condition reported significantly 
less depression (as measured by the depression subscale of the PHQ) at posttreatment than 
they did before treatment, whereas the waitlist control group showed no significant change 
over time, Condition x Time, F(1,21) = 16.2, p =.001, ηp2 = .435.  The effect size of this 
interaction was considered large. Both groups reported moderate levels of depression at 
baseline, whereas at post-treatment the treatment group reported mild depression and the 
waitlist control group continued to report moderate levels of depression. At baseline 73.5% 
of waitlist participants and 84.2% of treatment condition participants reported moderate or 
greater levels of depression on the PHQ.  At post-treatment, 94.7% of the veterans in the 
waitlist condition and 57% of veterans in the treatment condition reported moderate or 
greater levels of depression. 
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Figure 11. Depression ratings (PHQ) at pretreatment and posttreatment for the two 
conditions (treatment condition [CBT-I] compared with waitlist control condition).  
* Indicates the significant difference between CBT-I and Waitlist conditions at posttreatment. 
** Indicates the significant pretreatment to posttreatment difference for each condition. 
Table 9.  
Mean (and standard deviation) of CBT-I on Mood Symptoms: Treatment Condition (n = 14), 
Waitlist Condition (n = 12)A.      

 


 94.5 (29.7) 104.3 (36.8)  73.8 (36.6)a, ** 115.5 (26.2)  .25  22.3 (12.6) 24 (16.3)  17.1 (13.9) * 29.3 (13.3)  .214  20.3 (7) 22.6 (9.2)  16.1 (5.3) a, ** 24.1 (6)  .192  10.9 (4.8) 10.8 (5.9) 
 
11.6 (5.1) 11.2 (7.6) 
 
.002  21.9 (8.5) 22.6 (12.3) 
 
16.4 (10.7) a, * 25.9 (10.7) 
 
.180  14.2 (3.8) 14.1 (5.1)  11.6 (4.6) a, ** 16.6 (4.5)  .281 
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 15.8 (5.4) 18 (7.1)  11.8 (5.8) a, *** 19.6 (3.3)  .179  13 (3.3) 12.6 (5.1)  8.4 (4.7)c, ** 14.1 (2.8)  .435 
A : n=9 for waitlist condition responding to PHQ-9 
a
 p < .05; b p < .01; c p < .001 (letters indicate that CBT-I or Waitlist condition was 
significantly different at posttreatment compared to that condition’s baseline value) 
*p < .05; **p < .01; *** p < .001 (asterisks indicate that CBT-I and Waitlist conditions were 
significantly different at posttreatment.)  
 
Hypothesis #3 
The third hypothesis stated that veterans in the treatment condition would 
demonstrate gains on objective sleep measures as recorded by actigraphy. The mean baseline 
and posttreatment scores for those who completed treatment are listed in Table 10. It should 
be noted that of the fifteen veterans who completed treatment, four (26.6%) did not provide a 
complete set of actigraphy data. One veteran did not use the actigraph due to technical 
problems.  Three of these participants did provide baseline data but not two-week follow-up 
data because of errors in downloading the data or initializing the watch device and loss of the 
actigraphy. 
 As can be seen in Table 10, actigraphy scores demonstrated gains in sleep efficiency, 
F (1,9) =7.25, p < .05, ηp2 = .446. Prior to treatment, their recorded efficiency was below the 
ideal level of 85% (Morin, 2003), whereas after four sessions of CBT-I, veterans 
demonstrated efficient sleep. Significant gains in wake after sleep onset were also observed 
in the treatment condition, F(1,9) = 7.18, p < .05, ηp2 = .444. A trend towards significant 
decreases in sleep onset latency with treatment was also found, F(1,9) = 3.89, p = .08, ηp2  = 
.302. Lack of significance may be due to a lack of power (.422) in these analyses.  Analyses 
revealed no significant improvements in total sleep time. 
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Table 10. 
Means (and standard deviations) of Cognitive Behavioral Treatment of Insomnia (CBT-I) on 
Objective and Subjective Sleep Measures: Treatment Condition (n =9)   
  

 
  

 
  

 
        
* p < .05, ** p < .01, *** p < .001  (p values indicate significant changes between baseline 
and posttreatment.) 
 
Follow-Up Analyses 
 Repeated measures ANOVAs were conducted in order to examine whether veterans 
who completed treatment maintained improvements six to nine months post treatment. Only 
eleven participants completed follow-up data. Of these eleven, two sets of data were sent 
back to the VA but never found thus data from only nine participants were analyzed. Two of 
these nine participants were originally in the waitlist group and had crossed over to 
treatment. As a result of such low participation for follow-up assessment, follow-up analyses 
demonstrate statistical power below Cohen’s (1988) recommended .80 for all outcome 
variables with the exception of subjectively reported sleep efficiency (sleep diary), insomnia 
severity (ISI), overall sleep quality (PSQI) and fatigue (POMS fatigue subscale). 
Sleep Diary Variables. A repeated-measures ANOVA revealed that veterans 
reported significant increases in sleep efficiency between time points, F(2, 16) = 11.16, p 
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=.001, ηp2 = .58. Post-hoc analyses using Bonferroni correction revealed that sleep efficiency 
was significantly improved from baseline to posttreatment (p < .05) but not from baseline to 
follow-up assessment (p = .07). Pairwise comparisons demonstrated a significant decline in 
sleep efficiency from posttreatment to follow-up (p < .05). Despite this decline, at follow-up 
veterans still reported sleep efficiencies of 85.3%, which is considered just above the cutoff 
for clinically efficient sleep.  
Repeated measures ANOVAs also revealed that veterans reported significant 
improvements in sleep onset latency, wake after sleep onset, and total sleep time between 
time points: sleep onset latency (F(2, 16) = 3.61, p =.05, ηp2 = .311), wake after sleep onset 
(F(2, 16) = 5.67, p =.01, ηp2 = .415) and total sleep time (F(2, 16) = 4.23, p =.03, ηp2 = .346). 
Although pairwise comparisons using Bonferroni correction did not reveal significant 
differences between time-points (pretreatment, posttreatment, follow-up) for these sleep 
diary variables, veterans reported continued improvement from baseline. However they did 
not maintain posttreatment gains. Table 11 lists sleep diary variable means for all time points. 
Table 11.  
Means (and standard deviations) of CBT-I on Sleep Diary Variables 
 Baseline 
M (SD)  
PostTreatment 
M (SD) 
Follow-Up 
M (SD) 
Sleep Efficiency 76.3% (11.2) 90.9% (3.9)* 85.3% (4.6) 
Sleep Onset Latency 27.56 (23.5) 9.56 (6.9) 16.11 (8.5) 
Total Sleep Time 318.67 (73.2) 397 (78.9) 361 (65.6) 
Wake After Sleep 
Onset 
 
36.1 (25.2) 13.29 (7.8) 26.11 (18.2) 
* p < .05 (p values indicate significant changes between baseline and posttreatment.) 
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 Sleep Questionnaires.  As can be seen in Table 12, decreases in insomnia severity 
were maintained at follow-up assessment. A repeated-measures ANOVA determined that 
insomnia severity differed significantly between time points, F(2, 16) = 6.2, p =.01, ηp2 = .44. 
Post-hoc tests using the Bonferroni correction revealed that CBT-I was associated with a 
reduction in insomnia severity from pretreatment to posttreatment (p < .05) and from 
pretreatment to follow-up assessment (p < .05). No significant differences between means 
were observed from posttreatment to follow-up assessment (p > .18) suggesting that 
treatment gains were maintained from posttreatment to follow-up assessment.  
Consistent with hypotheses, increases in overall sleep quality (as measured by a 
decrease in the total score of the PSQI) were maintained at follow-up assessment. A repeated 
measures ANOVA found that overall sleep quality differed significantly between time points 
F(2, 16) = 21.8, p < .001, ηp2 = .73.  Post-hoc tests using the Bonferroni correction revealed 
that CBT-I was associated with an increase in overall sleep quality from pretreatment to 
posttreatment (p < .001) and from pretreatment to follow-up assessment (p < .05). No 
significant differences were observed from posttreatment to follow-up assessment (p > .06) 
suggesting that treatment gains were maintained over time. Analyses comparing beliefs about 
sleep over time (DBAS and DBAS-16) for those who completed treatment and follow-up 
assessment were underpowered and revealed no significant findings.  
Table 12.  
Means (and standard deviations) of CBT-I on Subjective Measures of Sleep 
 Baseline 
M (SD)  
PostTreatment 
M (SD) 
Follow-Up 
M (SD) 
Insomnia Severity  
 
18.22 (3.3) 11.89 (5.4)* 13.22 (4.9)* 
Pittsburgh Sleep 
Quality Index 
 
13.67 (3.3) 7.56 (3.6)** 9.89 (4.1)* 
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DBAS 
 
44.62 (7.8) 39.2 2(7.2) 44.01 (10.2) 
DBAS-16 50.77 (10.75) 41.56 (6) 47.12 (10.4) 
* p < .05, ** p < .001 (p values indicate significant changes from baseline.) 
PTSD Severity. Table 13 displays means for ratings of PTSD symptom severity 
(PSS-SR), PTSD related nighttime disturbances (PSQI-A), and PTSD nightmare frequency 
(PSQI-A, Question 1c). Repeated-measures ANOVAs for all sets of means were 
underpowered and revealed no significant differences over time.  
Table 13.  
Means (and standard deviations) of CBT-I on PTSD Symptom Severity 
 Baseline 
M (SD)  
PostTreatment 
M (SD) 
Follow-Up 
M (SD) 
PTSD Symptom 
Severity  
 
37.67 (11) 31.33 (15) 32.56 (14.8) 
PSQI-Addendum 
 
8.56 (4.2) 6.89 (5.5) 9.11 (5.8) 
PSQI-A (Question 
1c) 
1.78 (.97) 1.33 (1.2) 1.78 (1.2) 
 
 Mood Symptoms and Daytime Functioning. Table 14 displays means for ratings of 
mood and daytime functioning as measured by the POMS and the PHQ. A repeated-measures 
ANOVA found that ratings of fatigue differed significantly over time, F(2, 16) = 6.04, p 
=.01, ηp2 = .43. Post-hoc tests using the Bonferroni correction, however, were not statistically 
significant between time points, all p’s > .06. Repeated-measures ANOVAs for all other sets 
of means revealed no significant differences over time. 
Table 14.  
Means (and standard deviations) of CBT-I on Mood Symptoms and Daytime Functioning 
 Baseline 
M (SD)  
PostTreatment 
M (SD) 
Follow-Up 
M (SD) 
Overall Distress 
(POMS) 
80.89 (19.6) 66.22 (29.1) 77.44 (39.4) 
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Depression (POMS) 15.89 (9.2) 11.56 (12) 17.89 (13.86) 
Tension (POMS) 16.78 (6.3) 14.11 (6.2) 16.78 (8.33) 
Vigor (POMS) 11.56 (6.3) 12.11 (5.9) 12.67 (7.1) 
Anger (POMS) 19.34 (8.4) 13.22 (9.7) 17.33 (12.1) 
Confusion (POMS) 12.78 (2.6) 9.78 (3.5) 10.67 (4.1) 
Fatigue (POMS) 17.33 (5.19 10.44 (6.5) 14.78 (5.5) 
Depression (PHQ) 11 (2.9) 8.63 (6) 7.25 (4.9) 
 
Discussion 
 The purpose of the present study was to examine the efficacy of an insomnia 
intervention for OEF/OIF veterans diagnosed with PTSD and for whom insomnia was a 
major complaint. A randomized controlled trial design was used with participants 
randomized to either a treatment condition or a waitlist control condition. Based on a recent 
search of the literature, this is the first randomized control trial of CBT-I focusing on the 
OEF/OIF veteran population. Veterans in the treatment condition participated in four, one-
hour sessions of individual treatment. Treatment included the standard protocol for cognitive 
behavioral treatment of insomnia (CBT-I) and elements of imagery rehearsal therapy (IRT). 
It was hypothesized that individuals in the treatment condition would report greater 
improvements on subjective measures of sleep relative to veterans in a waitlist control 
condition. It was also hypothesized that individuals in the treatment condition would 
experience greater reductions in PTSD severity and improvement in mood and daytime 
functioning compared to their waitlist counterparts. Finally, it was hypothesized that veterans 
who participated in the intervention would report improvements on objective measures of 
sleep after treatment. The findings reported here support the three hypotheses proposed.  
  74
Overall, the results of this study suggest that an intervention consisting of CBT-I combined 
with elements of IRT is an effective insomnia treatment for OEF/OIF veterans struggling 
with PTSD.   
Effects of CBT-I and IRT on Subjective Measures of Sleep 
 In support of the first hypothesis, results from the present study indicate that veterans 
who participated in the intervention demonstrated greater improvements in subjectively 
measured sleep than waitlist control participants. Veterans in the treatment condition reported 
clinically meaningful improvements in sleep efficiency posttreatment. Sleep efficiency is 
considered normal at a rate of 85% or higher (Morin, 1993). In this study, 11% of veterans in 
the treatment condition reported sleep efficiency of 85% or higher at baseline. At 
posttreatment 75% of these treatment participants reported sleep efficiency equal to or 
greater than 85%. Veterans in the treatment condition also reported significant improvements 
in sleep onset latency and wake after sleep onset compared to their waitlist control 
counterparts. Improvements in sleep onset latency and wake after sleep onset translate to 
improvements in initiating sleep and maintaining sleep, respectively, two criteria that are 
assessed when diagnosing insomnia. Taken together, these findings suggest an overall 
improvement in sleep quality observed in veterans in the treatment group whereas veterans in 
the waitlist control group demonstrated no such improvement in sleep quality. The primary 
goal of CBT-I is to have the patient achieve improved sleep quality: more consolidated sleep 
that is less fragmented and has fewer disruptions. These findings suggest this primary goal 
was obtained for veterans who participated in treatment. Furthermore, these data, specifically 
the large effect sizes, are in line with those reported in the most recent meta-analysis of CBT-
I (Okajima et al., 2011). 
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Treatment did not significantly improve total sleep time. As discussed, the primary 
focus of this insomnia intervention is first to improve sleep quality (sleep efficiency, wake 
after sleep onset, sleep onset latency) and to ensure less fragmented and more consolidated 
sleep. Once good sleep quality has been established, quantity of sleep (i.e. total sleep time) 
can be added to and thus improved upon, if needed. As noted in the introduction, Morin 
(2004) argues that total sleep time, considered alone, is not a good index of insomnia because 
of individual differences in sleep needs, and thus might not be a good index of improved 
sleep. Furthermore, as Buysee (2010) and others have observed total sleep time is often 
reduced with concurrent improvements in sleep quality variables. Given that Total Sleep 
Time remained relatively the same for both groups in this study but that sleep efficiency, 
sleep onset latency and wake after sleep onset changed in the desired direction for veterans in 
the treatment group, it can be concluded that the intervention helped veterans achieve more 
consolidated and less fragmented sleep, which is a primary goal of the intervention.  
Furthermore, veterans in the treatment condition demonstrated clinically significant 
changes in sleep and met criteria for normal sleep at posttreatment as measured by subjective 
sleep questionnaires (ISI and PSQI). Veterans who were in the waitlist control condition 
reported no such change from baseline to posttreatment. Effect sizes for the significant 
baseline to posttreatment findings of insomnia severity and sleep quality were large 
(insomnia severity= .722 and sleep quality = .790). These large treatment effects compare to 
those reported by Ulmer and colleagues (2011). 
Posttreatment findings differed significantly between veterans in the treatment 
condition and those in the waitlist condition. Veterans who participated in treatment reported 
subthreshold insomnia after completion of CBT-I while their waitlist control counterparts 
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reported clinical levels of insomnia of moderate severity over time as measured by the ISI. 
Similarly, an increase in sleep quality as measured by the PSQI was observed in the 
treatment group compared to the waitlist control group.  
A trend approaching a significant interaction was observed for beliefs about sleep, as 
measured by the Dysfunctional Beliefs and Attitudes About Sleep Scale (DBAS) and DBAS-
16. From baseline to posttreatment, veterans in the treatment group reported more functional 
beliefs about sleep, and this change over time was significant (Table 18, Appendix J). 
Veterans in the treatment condition specifically reported more realistic beliefs about the role 
of medication on sleep. Veterans in the waitlist condition demonstrated relatively no change 
in their sleep cognitions from baseline to posttreatment. These posttreatment findings were 
significant between treatment and waitlist conditions.  
Studies similar to the one reported here (Ulmer et al., 2010; Swanson et al., 2009), 
have not assessed for changes in cognitions about sleep as measured by the DBAS or DBAS-
16. This measure is a standard instrument in the insomnia intervention literature (Buysse et 
al., 2006) as it is sensitive to changes in beliefs about sleep as a result of cognitive-behavioral 
treatment for insomnia. Future research should continue to assess the impact of CBT-I on 
cognitions about sleep with this population and explore the possibility that cognitive shifts 
are perhaps more difficult with this veteran population.  
Overall, results from this study demonstrate that CBT-I combined with elements of 
IRT is quite effective in improving sleep with an OEF/OIF veteran population. These 
improvements are consistent with current research (Swanson et al., 2009; Ulmer et al., 2011) 
demonstrating CBT-I alone or in combination with elements of IRT show promising 
outcomes with veterans and, more specifically to this study, that the intervention works well 
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with veterans recently deployed to Iraq and/or Afghanistan. The treatment used in this study 
produced significant treatment effects in many of the same domains as those found in the 
clinical outcomes described by Ulmer and colleagues (2011), including subjectively 
measured, sleep efficiency, sleep onset latency, wake after sleep onset, sleep quality (PSQI), 
and insomnia severity (ISI). These results are also consistent with those observed by 
Swanson and colleagues (2009) where significant treatment effects of a combined approach 
(CBT-I and IRT) were seen for sleep quality and insomnia severity. This study is a novel 
contribution to the literature as it is the first to show these sleep improvements in a 
randomized control trial with a focus on OEF/OIF veterans.  
Effects of CBT-I and IRT on PTSD Symptoms 
 PTSD Symptom Severity. In support of the second hypothesis, veterans in the 
treatment condition demonstrated significant reductions in trauma symptom severity, while 
waitlist control participants’ scores reflected a nonsignificant trend toward increasing 
symptom severity from baseline to posttreatment. These findings and the large effect sizes 
are also consistent with those presented by Ulmer and colleagues (2011) where PTSD 
symptom severity decreased (as measured using the PTSD Checklist- Military Version).  
Interestingly, interventions directly addressing PTSD symptoms do not have an equivalent 
carry over effect for insomnia (Belleville, Guay, & Marchand, 2010). 
As noted in the Demographics section of Results, 65% of veterans in the study were 
concurrently participating in individual and/or group treatment. Follow-up analyses revealed 
that of these veterans, those in the CBT-I condition showed reduced PTSD severity from pre 
to posttreatment while their waitlist counterparts reported an increase in PTSD symptom 
severity over the same period of time despite participation in PTSD treatment. Similarly, the 
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veterans receiving CBT-I but not receiving PTSD treatment reported reduced PTSD severity 
from pre to posttreatment while the one veteran receiving neither CBT-I nor PTSD treatment 
showed an increase in PTSD symptom severity. This demonstrates that a brief intervention of 
CBT-I can reduce PTSD symptom severity in OEF/OIF veterans, possibly independent of 
PTSD treatment. Given the mounting prevalence of PTSD diagnoses in this veteran 
population, such an intervention offers an efficient and accessible adjunct to current 
treatments of PTSD.  Future research should more systematically follow and measure 
participant involvement in PTSD treatment along with CBT-I as a means of assessing the 
therapeutic effect of using CBT-I as an adjunctive therapy to the gold standard, evidence-
based PTSD treatments. 
PTSD-Specific Sleep Disturbances. Veterans who participated in treatment also 
reported significant decreases in PTSD-specific sleep disturbances (based on results from the 
PSQI-A) compared to veterans in the waitlist condition, whose scores trended towards an 
increase in PTSD-specific sleep disturbances, further supporting hypothesis two. These 
findings differ from those reported by Ulmer and colleagues (2011) who did not observe a 
significant difference between groups at posttreatment for PTSD-specific disruptive 
nocturnal behaviors, as measured by the PSQI-A. This may have been related to the fact that 
the OEF/OIF veterans had PTSD that was of a shorter duration, and therefore more 
responsive to intervention, than the veterans who participated in the Ulmer et al. study.  
Additionally, Ulmer et al. (2011) demonstrated trends that may have proved significant with 
a larger sample size than utilized in the pilot study (9 in each group).  
Exploratory analyses were conducted to assess the Condition x Time interaction of 
the traumatic nightmare item on the PSQI-A since traumatic nightmares were a target of 
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intervention. The analysis revealed that the groups significantly differed with treatment. The 
treatment group reported a decrease in nightmares at posttreatment and the waitlist group 
reported an increase in traumatic nightmare frequency, although neither of these trends was 
statistically significant. For the variable of nightmare frequency, the Ulmer et al. study 
(2011) did yield significant reductions in nightmares from treatment.  However, it should be 
noted that the Ulmer study required that participants report having nightmares to be eligible 
and the participants did, in fact, report more than four nightmares per week on average.  This 
is contrasted to the present study in which nightmare frequency was not a requirement for 
eligibility.  As such, the present study may not have had enough power to detect modest 
changes in nightmare frequency relative to the Ulmer study (2011).  Additionally, the present 
study failed to include nightmare frequency as a measure on the sleep diary, as was done in 
the Ulmer study, thereby providing a much more sensitive and continuous measure of 
nightmare frequency.  Future studies should add this measure to the daily diary report, as was 
done in the Ulmer study.   
 It is possible that some of the IRT skills acquired during treatment protected veterans 
from experiencing an increase in nightmare frequency, unlike the control group, but was not 
sufficient for generating a decrease in nightmares. The abbreviated IRT used in this research 
was based on a study examining behavioral insomnia treatment for adult violent crime 
victims diagnosed with PTSD (Germain et al., 2007), and not with a combat population. It is 
possible that a combat-population, which likely has had more trauma exposure, would benefit 
from a more comprehensive and longer dosage of IRT than was used in this study. To date, 
the efficacy of IRT on PTSD-specific nightmares has been well studied in non-veteran 
populations (Germain, 2007; Krakow et al., 2002; Krakow et al., 2001a; Krakow et al., 
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2001b). Numerous uncontrolled pilot studies conducted with veteran populations have 
demonstrated promising findings (Nappi et al., 2010, Harb et al., 2009; Swanson et al., 2009; 
Lu et al., 2009; Moore & Krakow, 2007). However, the handful of controlled studies that 
have been conducted with a veteran population have not been as promising. For instance, in a 
recent randomized control trial (Ulmer et al., 2011) that most closely parallels the study 
reported here, a combined intervention implementing only three sessions each of CBT-I and 
IRT with a mixed veteran population did not result in a significant Condition x Time 
interaction for trauma-related sleep quality as measured by the PSQI-A although the data 
trended in the anticipated direction. Given the amount of trauma to which a combat 
population is exposed, there may have been too few treatment sessions to effectively 
administer both CBT-I and elements of IRT. Standard IRT protocol recommends four 
sessions (Krakow & Zadra, 2010). Given the findings from the Ulmer study (2011) and the 
study reported here, it stands to reason that an increase in the number of sessions could 
potentially produce different outcomes with respect to nightmare frequency. Future research 
should also seek to determine the proper dose of sessions that would meet the needs of the 
insomnia and trauma-related sleep disturbances seen in combat veterans.  
That being said, in another randomized control trial, Cook et al. (2010) found that 
after participating in six 90-minute sessions of IRT, Vietnam War veterans did not report a 
significant change in traumatic nightmare frequency compared to an active psychotherapy 
condition.  The control in this study was a psychotherapy condition rather than a waitlist 
control as seen in Ulmer (2011) and the study reported here. Clearly, more controlled trials 
examining the effectiveness of IRT in veteran populations are warranted.  
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Furthermore, given the unique experience of the OEF/OIF veteran population with 
multiple deployments and consequently multiple traumatic events, future research should 
also explore how these veterans differ from other veteran populations with respect to their 
response to IRT. As noted previously, the therapist providing treatment experienced 
significant difficulty engaging many of the participants in the rescripting process of IRT. 
Issues that arose when introducing IRT stemmed either from participants’ difficulty using 
imagery or in changing a traumatic nightmare effectively. Participants also appeared 
reluctant to discuss the traumatic memories that shape their nightmares. As a result many 
participants were not successful at practicing their rescripted dreams on a daily basis outside 
of therapy sessions. Lu et al. (2009) experienced similar difficulty in their study assessing 
IRT as monotherapy with male veterans of various service eras. These researchers detail 
participant difficulty focusing on or creating a tolerable dream and thus low compliance rate 
with these veterans practicing rescripted dreams. They conclude that IRT is likely more 
beneficial when provided as adjunctive therapy.  
With respect to the specific OEF/OIF veteran population, recent research discusses 
the reluctance that these younger veterans demonstrate in engaging in and/or committing to 
mental health treatment (Hoge et al., 2004).  Harb and colleagues (2009) made a concerted 
effort to sidestep this issue with Iraq veterans by waiting until the fourth session to introduce 
IRT after therapeutic alliance had already been established with three sessions of CBT-I. 
Their reasoning centered on the premise that this population of veterans is likely new to 
psychotherapy and would thus be hesitant to share distressing nightmares upon initial contact 
with the therapist. In the study presented here, IRT was introduced in the first session with 
the rationale that participants would need the time to practice the rescripted dream with the 
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support of the therapist. It is unclear whether the timing of IRT in this study was 
compromised by the participants’ lack of familiarity and thus lack of therapeutic alliance 
with the therapist at the first session.   
Despite these limitations, participants reported trends in the anticipated direction for 
nightmare frequency following treatment and a more sensitive measure of nightmare 
frequency might have detected more modest changes. Furthermore, veterans in this study 
who participated in treatment reported an overall significant decrease in PTSD-related sleep 
disturbances as a result of treatment compared to waitlist counterparts. Veterans in the 
waitlist control condition showed an increase in nightmare frequency while treatment 
participants showed trends demonstrating a decrease in nightmare frequency. These findings 
suggest that the intervention was associated with a reduction in PTSD-specific sleep 
disturbances and provide support for the second hypothesis. Furthermore, this is the first 
study to demonstrate these effects with a focus on an OEF/OIF veteran population. 
Effect of CBT-I on Mood Symptoms 
 Depression. In further support of hypothesis two, PHQ depression ratings for 
veterans in the treatment condition decreased with treatment while depression ratings for the 
waitlist group increased with time, though the change was not significant. Participants from 
both groups reported moderate levels of depression at baseline. After treatment, veterans in 
the treatment group reported mean scores reflecting mild levels of depression while waitlist 
participants continued to report moderate depression. These findings support the claim that 
improvements in sleep can lead to improvements in comorbid issues such as depression, 
(Taylor, Lichstein, Weinstock, Sanford & Temple, 2007; Manber, Edinger, & Gress, 2008; 
Watanabe, 2011) although the intervention was not targeted for treatment of depression. 
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These results are consistent with the current literature demonstrating that CBT-I is effective 
in treating both sleep disturbances associated with insomnia and decreasing depressive 
symptoms (Watanabe, 2011; Manber et al., 2008). These findings stand out in the literature 
as this study is the first to show these effects with an OEF/OIF veteran cohort.  
 Overall Distress, Mood, and Daytime Functioning. Consistent with the above 
findings, these data also revealed improvements in overall distress as well as in tension, 
fatigue, anger, and confusion (as measured by the POMS) as a result of the intervention. 
Decreases in these emotions were not observed in waitlist controls. Similar to the findings 
associated with depression, these results demonstrate the global benefits of CBT-I and/or IRT 
above and beyond treating insomnia. A thorough search of the literature did not come up 
with other studies of PTSD combat populations looking at the effects of CBT-I and IRT on 
daytime symptoms measured by the POMS or similar instruments. Thus the findings of this 
study are unique in showing improvements in mood and daytime functioning in veterans 
after participation in CBT-I. 
Effects of CBT-I and IRT on Objective Measures of Sleep 
 In support of the third hypothesis, veterans in the treatment condition demonstrated 
significant improvements on several objective sleep outcome variables after treatment. 
Actigraphy recordings of these veterans’ sleep patterns revealed significant improvements in 
sleep efficiency and wake after sleep onset (WASO) from baseline to posttreatment, with 
large effect sizes of .446 and .444, respectively. In the recent meta-analysis looking at the 
effectiveness of CBT-I (Okajima et al., 2011) demonstrated that across 10 studies, 
objectively measured sleep efficiency (as measured by actigraphy and/or polysomnography) 
improved an average of four percent from baseline to posttreatment. The study presented 
  84
here demonstrates sleep efficiency improvements of over five percent. Sleep onset latency 
was also reduced with a large effect size, but this change was not statistically significant, 
F(1,9) = 3.89, p = .08, ηp2  = .302. Significant improvements were not found for total sleep 
time. This finding is in line with conclusions drawn from the aforementioned meta-analysis 
(Okajima et al., 2011), in which no significant improvements were found between baseline 
and end of treatment for objectively measured total sleep time.  
Comparison of Objective and Subjective Measures of Sleep within Treatment 
Condition 
 In this study, self-report data of sleep (as measured by sleep diaries) reflect 
objectively recorded measures of sleep (actigraphy) in terms of treatment outcome (see Table 
10 in Results section). Analyses of both subjective and objective measures found 
improvements in sleep efficiency, wake after sleep onset, and sleep onset latency (although 
the objectively reported sleep onset latency only trended towards significance). Effect sizes 
for all outcomes for the those who participated in treatment were large: Sleep Efficiency 
(subjective: ηp2 = .721; objective: ηp2 = .446); Wake After Sleep Onset (subjective: ηp2 = 
.369; objective: ηp2 = .444); and Sleep Latency (subjective: ηp2 = .421; objective: ηp2 = . 
.286). Compared to the medium effect sizes reported for the same objective variables in the 
recent meta-analysis (Okajima et al., 2011), the effects observed in this study stand out in the 
literature as greater than the average objective improvement reported across CBT-I studies. 
As noted previously, compliance with wearing the actigraph was not as high as 
compliance in completing sleep diaries. Thus the actigraphy data do not reflect the entire 
cohort of veterans who participated in and completed treatment.   However, the subset of data 
provides objective verification of the self-report data, which is inherently more vulnerable to 
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positive expectancy bias and demand characteristics.  The latter is particular problematic in a 
situation like this where the interventionist is also conducting the study.   
 Numerous studies have found a discrepancy between objective and subjective 
measures (Germain, 2009; Habukawa et al., 2007; Breslau et al., 2004; Klein, Koren, Arnon 
& Lavie, 2003; Lavie, 2001). Furthermore, in a 2006 article that set forth recommendations 
for a standard research assessment of insomnia, researchers cautioned that while actigraphy 
corresponds highly with polysomnography, it is less reliable compared to sleep diaries and 
tends to “overscore” sleep in individuals with insomnia (Buysse, Ancoli-Israel, Edinger, 
Lichstein & Morin 2006). The study reported here, however, demonstrated relative 
consistency between sleep diary and actigraphy outcome variables. These findings more 
closely relate to current literature demonstrating that the often observed discrepancy between 
objective and subjective sleep outcome variables can be mitigated when objective measures 
are used in the home (as in this study) rather than in a sleep laboratory or sleep center 
(Germain, Hall, Shear, Nofzinger, & Buysse, 2006; Calhoun et al., 2007). 
Directions for Future Research 
 The present study suggests a number of directions for future research. First, only one 
therapist conducted the intervention rather than multiple providers. Future studies assessing 
the efficacy of behavioral insomnia treatments at VA Medical Centers should consider 
including multiple providers, as this would more realistically reflect how treatment would be 
delivered within this setting.  Having only one therapist conduct treatment and assessment 
was also a limitation of this study and thus future research should have separate researchers 
conducting treatment and assessment. Furthermore, future research studying the effects of 
CBT-I with this veteran population should track medication usage and prescription changes 
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that occur while the study is ongoing. Because this was not systematically followed in this 
study, we were unable to determine the role that medication played in changes in sleep 
behavior or emotional functioning.  
 Another limitation of this study is the low response rate achieved for follow-up data.1 
Of the few studies with combat veterans published in which follow-up data was collected, 
low response rate did not appear to be an issue (Lu et al., 2009; Forbes et al., 2003). One 
explanation for this study’s low response rate at follow-up might be found in gaining a better 
understanding of this particular veteran population’s attitude towards mental health 
treatment. In the recent study conducted by Ulmer and colleagues (2011), which included 
veterans of all combat theaters with PTSD-related insomnia, the only veterans who dropped 
out of the study were OEF/OIF veterans. This is consistent with findings suggesting that 
these veterans are reluctant to use VA mental health services due to stigma and barriers to 
care such as embarrassment and being perceived as weak (Pietrzak, 2009). Although we 
cannot conclude that not using VA services is a result of such noted stigmas and barriers, 
these participants’ lack of response might be the result of a greater dismissal of VA mental 
health services.  
 As noted earlier, if chronic nightmares are going to be a focus of treatment, and they 
should given that they maintain difficulties with sleep (DeViva, Zayfert, & Mellman, 2004; 
Germain & Nielsen, 2003; Krakow et al., 2001), veterans might benefit from additional 
sessions of treatment that more comprehensively incorporate and balance CBT-I with IRT. 
To date, research assessing the appropriate number of sessions and the balance of CBT-I and 
IRT to be used with recently deployed veterans has not been conducted. As seen in Table 1 in 
the review of literature examining both veteran and non-veteran populations, the studies that 
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have assessed these treatment modalities with a PTSD population have varied in numbers of 
session (from one to ten) and in implementation of treatment (i.e., CBT-I alone, IRT alone, or 
a combination of CBT-I and IRT). Future research should seek to find how many sessions 
this protocol would ideally entail when used with a veteran population, define the balance 
between CBT-I and IRT, and determine whether the two treatments should be delivered 
within the same intervention protocol or whether they should be delivered independent of 
each other, either simultaneously or in sequence.   
Study Implications and Clinical Applications 
 The present research also has a number of important implications. Given the 
reduction of both insomnia and PTSD symptoms in this study, treatment providers should 
thus assess for severity of insomnia as a standard of course with PTSD patients and, if 
present, should incorporate CBT-I into treatment. The treatment itself is relatively brief, cost-
effective, and can be delivered as individual psychotherapy or within a group format (Bastien 
et al., 2004). The results of this study encourage such a treatment approach with OEF/OIF 
veterans. 
In this study, veterans who participated in treatment reported both better sleep quality 
and a decrease in their PTSD symptom severity. Previous research shows that mood 
symptoms can be mitigated by improved sleep and that insomnia can be a predisposing factor 
of mood symptoms such as depression (Perlis et al., 2006) or PTSD (Koren et al., 2002; 
Picchioni et al., 2010), and also points to the predictive nature of disturbed sleep/chronic 
nightmares for consequent development of PTSD (Koren et al., 2002; Picchioni et al., 2010). 
Although the present research cannot determine such causality or the directional relationship 
of sleep and PTSD, empirical studies looking at this relationship seem warranted and 
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clinically relevant. For instance, might CBT-I in a non-PTSD sample of OEF/OIF veterans 
have protective and preventive effects for the development of future PTSD? In the meantime, 
clinicians should make a habit of assessing for sleep disturbances in vulnerable but non-
PTSD diagnosed OEF/OIF veterans as insomnia and chronic nightmares might be early 
harbingers of an emerging PTSD disorder. 
Conclusion 
 This study demonstrates strong support that a cognitive-behavioral based approach to 
treating combat-related, posttraumatic insomnia and nightmares is an effective and efficient 
adjunctive therapy to currently delivered PTSD exposure treatments provided at VA medical 
centers. The findings confirm that CBT-I is beneficial and therapeutic for OEF/OIF veterans 
diagnosed with PTSD for whom insomnia is a major concern. The findings also demonstrate 
that this intervention, which targets both insomnia and nightmares, has large effects in 
improving sleep quality and insomnia severity, and decreasing PTSD symptom severity, 
PTSD-related sleep disturbances, depression, and overall distress in OEF/OIF veterans.  This 
is the first study that uses a combined CBT-I and IRT approach targeting specifically the 
OEF and OIF veteran population. This is also the first study to incorporate both objective and 
subjective measures of sleep and to assess for daytime functioning with this veteran 
population. Given the success of the intervention on sleep, PTSD-specific sleep disturbances, 
PTSD symptom severity, mood and daytime functioning, this study offers an important 
contribution to the literature and has timely implications in validating the use of this 
treatment protocol with this current veteran population. Given the staggering numbers of 
these veterans who are at risk for suffering from PTSD and PTSD-related sleep disturbances, 
implementation of cognitive-behavioral based treatments for PTSD related insomnia and 
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nightmares within a PTSD treatment program is an important and necessary step for mental 
health clinics at VA medical centers to consider. 
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Footnotes 
 
1
 Once the study investigator was no longer on site at the McGuire VAMC, due to 
beginning internship, collecting data and contacting veterans became more difficult. During 
the active stage of the study, veterans were easier to contact as they were often seen after 
groups or appointments they already had scheduled at the VA and thus scheduling and 
treatment could be conducted at these times. Not being present at the VA proved to be a 
significant obstacle to this study in maintaining communication with many of the 
participants. Furthermore, two of the returned information packets were never found, 
although participants confirmed they had sent them in. The loss of these packets further 
underscores the obstacle that was caused by the physical absence of the main investigator 
once the active phase of the study was completed. 
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Sleep Diary
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Appendix B 
 
PTSD Symptom Scale: Self-Report Version (PDS; Foa et al., 1997) 
 
Participant ____________________________________ Date___________  
Directions: Below is a list of the problems that people sometimes have after experiencing a 
traumatic event. Read each one carefully and fill in the number (0-3) that best describes how 
often that problem has bothered you in the past 2 weeks. Rate each problem with respect to 
the traumatic event that brought you into treatment.  
0 = Not at all or only one time  
1 = Once per week or less/once in a while  
2 = 2 to 4 times per week/half the time  
3 = 5 or more times per week/almost always  
Items 0 1 2 3 
1. Having upsetting thoughts or images about the traumatic event that came into your head 
when you didn’t want them to?  
    
2. Having bad dreams or nightmares about the traumatic event?      
2a. Having these bad dreams always center on being killed?      
3. Reliving the traumatic event, acting or feeling as if it were happening again?      
3a. Reliving the traumatic event as if I am moving in a rewind motion?      
4. Feeling EMOTIONALLY upset when you were reminded of the traumatic event (for 
example feeling scared, angry, sad, guilty, etc. 
    
5. Experiencing PHYSICAL reactions (for example, break out in a sweat, heart beats fast) 
when you were reminded of the traumatic event?  
    
6. Trying not to think about, talk about, or have feelings about the traumatic event?      
6a. And when I try hard enough NOT to think about the traumatic event I feel dizzy?      
7. Trying to avoid activities, people, or places that remind you of the traumatic event?      
8. Not being able to remember an important part of the traumatic event?     
9. Having much less interest or participating much less often in important activities?      
9a. Having much MORE interest in activities that are unimportant?     
10. Feeling distant or cut off from people around you?      
11. Feeling emotionally numb (for example, being unable to cry or unable to have loving 
feelings)  
    
11a. Feeling emotionally transparent (for example, feeling like people are unable to see me)      
12. Feeling as if your future plans or hopes will not come true (for example, you will not 
have a career, marriage, children, or a long life)? 
    
13. Having trouble falling or staying asleep?  
14. Feeling irritable or having fits of anger?  
    
15. Having trouble concentrating (for example, drifting in and out of conversations, losing 
track of a story on television, forgetting what you read)?  
    
16. Being overly alert (for example, checking to see who is around you, being uncomfortable 
with your back to the door, etc.)?  
    
16a. Being overly aware of sensations or changes in my body?      
17. Being jumpy or easily startled (for example, when someone walks up behind you)?      
17a. Being acutely aware of smells, especially body odor?      
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Appendix C 
 
The Pittsburgh Sleep Quality Index (PSQI) is protected by copyright so it is not reproduced 
in this document.  
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Appendix D 
 




 
 



 



 



 



 



 



 





 

 

      
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
 

      

 



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Appendix E 
 
The Insomnia Severity Index (ISI) is protected by copyright so it is not reproduced in this 
document.  
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Appendix F 
Beliefs and Attitudes about Sleep Scale 
 
Several statements reflecting people’s beliefs and attitudes about sleep are listed below.  
Please indicate to what extent you personally agree or disagree with each statement.  
There is no right or wrong answer.  For each statement, place a mark (/) along the line 
wherever your personal rating falls.  Try to use the whole scale, rather than placing 
your marks at one end of the line. 
 
1. I need 8 hours of sleep to feel refreshed and function well during the day. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
   
2. When I don’t get a proper amount of sleep on a given night, I need to catch up on the next 
day by napping or on the next night by sleeping longer. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
 
3. Because I am getting older, I need less sleep. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
 
4. I am worried that if I go for one or two nights without sleep, I may have a nervous 
breakdown. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
  
5. I am concerned that chronic insomnia may have serious consequences for my physical 
health. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
 
6. By spending more time in bed, I usually get more sleep and feel better the next day. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
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7. When I have trouble getting to sleep, I should stay in bed and try harder. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
 
8. I am worried that I may lose control over my abilities to sleep. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
 
9. Because I am getting older, I should go to bed earlier in the evening. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
 
 
 
10. After a poor night’s sleep, I know that it will interfere with my daily activities the next 
day. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
 
11. In order to be alert and function well during the day, I am better off taking a sleeping pill 
rather than having a poor night’s sleep. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
 
12. When I feel irritable, depressed, or anxious during the day, it is mostly because I did not 
sleep well the night before. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
 
13. Because my bed partner falls asleep as soon as his or her head hits the pillow and stays 
asleep through the night, I should be able to do so too. 
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 Strongly     ____________________________________ Strongly  
 disagree        agree   
 
14. I feel that insomnia is basically the result of aging, and there isn’t much that can be done 
about this problem. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
 
15. I am sometimes afraid of dying in my sleep. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
 
16. When I have a good night’s sleep, I know that I will have to pay for it on the following 
night. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
 
17. When I sleep poorly on one night, I know it will disturb my sleep schedule for the whole 
week. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
 
18. Without an adequate night’s sleep, I can hardly function the next day. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
 
19. I can’t predict whether I’ll have a good or poor night’s sleep. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree  
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20. I have little ability to manage the negative consequences of disturbed sleep. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
 
21. When I feel tired, have no energy, or just seem not to function well during the day, it is 
generally because I did not sleep well the night before. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
 
22. I get overwhelmed by my thoughts at night and often feel I have no control over my 
racing mind. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
 
23. I feel I can still lead a satisfactory life despite sleep difficulties. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree  
  
24. I believe insomnia is essentially the result of a chemical imbalance. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
 
25. I feel insomnia is ruining my ability to enjoy life and prevents me from doing what I 
want. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
 
26. I avoid or cancel obligations (social, family, occupational) after a poor night’s sleep. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
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27. A “nightcap” before bedtime is a good solution to sleep problems. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
 
28. Medication is probably the only solution to sleeplessness. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
 
29. My sleep is getting worse all the time, and I don’t believe anyone can help. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
 
30. It usually shows in my physical appearance when I haven’t slept well. 
 
 Strongly     ____________________________________ Strongly  
 disagree        agree   
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Appendix G 
 
TREATMENT EVALUATION QUESTIONNAIRE 
Pre       Post 
 
Name:    Age : 
Date: 
 
 
 
1. Does this treatment and its rationale make sense to you? 
 
NOT AT ALL   _______________________________________VERY MUCH SO 
 
2. How acceptable do you consider this insomnia treatment? 
 
NOT AT ALL        VERY 
ACCEPTABLE________________________________________ACCEPTABLE 
 
3. How suitable is this treatment for your sleep problem? 
  
NOT AT ALL         VERY 
SUITABLE      _________________________________________  SUITABLE 
 
4. How effective do you expect this treatment to be for your sleep problem? 
 
 NOT AT ALL         VERY 
 EFFECTIVE    _________________________________________  EFFECTIVE 
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Appendix H 
The Patient Health Questionnaire (PHQ) is protected by copyright so it is not reproduced in 
this document.  
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Appendix I 
The Profile of Mood States (POMS) 
  118
Below is a list of words that describe feelings people have. Please read each one 
carefully. Then circle the number under the answer which best describes HOW 
YOU HAVE BEEN FEELING DURING THE PAST WEEK INCLUDING 
TODAY. 
 
 
 
 
1. Friendly     0   1   2   3   4 18. Blue       0   1   2   3   4 
 
2. Tense     0   1   2   3   4 19. Energetic      0   1   2   3   4 
 
3. Angry     0   1   2   3   4 20. Panicky   0   1   2   3   4 
 
4. Worn out     0   1   2   3   4 21. Hopeless   0   1   2   3   4 
 
5. Unhappy     0   1   2   3   4 22. Relaxed   0   1   2   3   4 
 
6. Clear-headed    0   1   2   3   4 23. Unworthy   0   1   2   3   4 
 
7. Lively     0   1   2   3   4 24. Spiteful   0   1   2   3   4 
 
8. Confused     0   1   2   3   4 25. Sympathetic  0   1   2   3   4 
 
9. Sorry for things done 0   1   2   3   4 26. Uneasy   0   1   2   3   4 
 
10. Shaky     0   1   2   3   4 27. Restless   0   1   2   3   4 
 
11. Listless                     0   1   2   3   4           28. Unable to concentrate       0   1   2   3   4 
 
12. Peeved     0   1   2   3   4 29. Fatigued   0   1   2   3   4 
 
13. Considerate    0   1   2   3   4 30. Helpful   0   1   2   3   4 
 
14. Sad                0   1   2   3   4 31. Annoyed   0   1   2   3   4 
 
15. Active     0   1   2   3   4 32. Discouraged  0   1   2   3   4 
 
16. On edge                0   1   2   3   4 33. Resentful   0   1   2   3   4 
 
17. Grouchy                0   1   2   3   4 34. Nervous   0   1   2   3   4 
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35. Lonely  0   1   2   3   4  53. Furious   0   1   2   3   4 
 
36.  Miserable  0   1   2   3   4  54. Efficient   0   1   2   3   4 
 
37. Muddled  0   1   2   3   4  55. Trusting   0   1   2   3   4 
 
38. Cheerful  0   1   2   3   4  56. Full of pep   0   1   2   3   4 
 
39. Bitter  0   1   2   3   4  57. Bad-tempered  0   1   2   3   4 
 
40. Exhausted  0   1   2   3   4  58. Worthless   0   1   2   3   4 
 
41. Anxious  0   1   2   3   4  59. Forgetful   0   1   2   3   4 
 
42. Ready to fight 0   1   2   3   4  60. Carefree      0   1   2   3   4 
 
43.  Good natured 0   1   2   3   4  61. Terrified   0   1   2   3   4 
 
44. Gloomy  0   1   2   3   4  62. Guilty   0   1   2   3   4 
 
45. Desperate  0   1   2   3   4  63. Vigorous   0   1   2   3   4 
 
46. Sluggish  0   1   2   3   4  64. Uncertain about things 0   1   2   3   4 
 
47. Rebellious  0   1   2   3   4  65. Bushed   0   1   2   3   4 
 
48.  Helpless  0   1   2   3   4 
 
49. Weary  0   1   2   3   4 
 
50. Bewildered 0   1   2   3   4 
 
51.  Alert  0   1   2   3   4 
 
52.  Deceived  0   1   2   3  4
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Appendix J 
 
Analysis of Variance Tables for All Analyses 
 
Table 15. 
Repeated-Measures Multivariate Analysis of Variance: Effects of Cognitive Behavioral 
Treatment of Insomnia (Condition X Time) on Sleep Diary 
Source 
 
df Error  df F ηp2 P 
Sleep Diary 4 29 5.42 .428 .002 
 
Table 16. 
Repeated-Measures Analysis of Variance for Effects of Cognitive Behavioral Treatment of 
Insomnia (Condition X Time) on Sleep Diary Variables 
Variable 
 
df Error df F ηp2 P 
Sleep 
Efficiency 
 
1 32 23.08 .419 .000 
Sleep Onset 
Latency 
 
1 32 15.23 .322 .000 
Total Sleep 
Time 
 
1 32 3.31 .094 .078 
Wake After 
Sleep Onset 
1 32 7.43 .188 .010 
 
Table 17. 
Repeated-Measures Analysis of Variance for Effects of CBT-I over time on Sleep Diary 
Variables Within Each Group 
Variable 
 
Df Error df F ηp2 P 
   Treatment Condition   
Sleep 
Efficiency 
 
1 17 30.17 .64 .000 
Sleep Onset 
Latency 
 
1 17 16.23 .488 .001 
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Total Sleep 
Time 
 
1 17 3.57 .174 .076 
Wake After 
Sleep Onset 
1 17 15.82 .482 .001 
   Waitlist Control   
Sleep 
Efficiency 
 
1 15 .279 .018 .605 
Sleep Onset 
Latency 
 
1 15 1.55 .094 .232 
Total Sleep 
Time 
 
1 15 .31 .020 .584 
Wake After 
Sleep Onset 
1 15 .043 .003 .838 
 
Table 18. 
Repeated-Measures Analysis of Variance for Effects of CBT-I (Condition X Time) on 
Insomnia Severity and Overall Sleep Quality  
Variable 
 
Df Error df F ηp2 p 
Insomnia 
Severity (ISI) 
 
1 35 16.24 .317 .000 
Overall Sleep 
Quality 
(PSQI) 
 
1 35 25.28 .419 .000 
Beliefs About 
Sleep 
(DBAS-16) 
1 34 3.42 .091 .073 
 
Table 19. 
Repeated-Measures Analysis of Variance for Effects of CBT-I over time for Insomnia 
Severity and Overall Sleep Quality 
Variable 
 
Df Error df F ηp2 p 
   Treatment Condition   
Insomnia 
Severity (ISI) 
 
1 19 22.4 .541 .000 
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Overall Sleep 
Quality 
(PSQI) 
 
1 19 27.58 .59 .000 
Beliefs 
About Sleep 
(DBAS-16) 
 
1 18 6.05 .251 .024 
   Waitlist Control   
Insomnia 
Severity (ISI) 
 
1 16 0 0 1.0 
Overall Sleep 
Quality 
(PSQI) 
 
1 16 2.11 .117 .165 
Beliefs 
About Sleep 
(DBAS-16) 
1 16 .51 .003 .824 
 
Table 20. 
Repeated-Measures Analysis of Variance for Effects of Cognitive Behavioral Treatment of 
Insomnia (Condition X Time) on PTSD Symptom Severity and PTSD Related Nighttime 
Disturbances 
Variable 
 
Df Error df F ηp2 p 
PTSD 
Symptom 
Severity 
 
1 25 16.71 .401 .000 
PSQI-A 1 23 7.3 .241 .01 
 
Table 21. 
Repeated-Measures Analysis of Variance for Effects of CBT-I over time for PTSD Symptom 
Severity and PTSD Related Nighttime Disturbances 
Variable 
 
Df Error df F ηp2 p 
   Treatment Condition   
PTSD 
Symptom 
Severity 
 
1 14 12.39 .469 .003 
PSQI-A 1 14 6.62 .321 .022 
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   Waitlist Control   
PTSD 
Symptom 
Severity 
 
1 11 5.58 .336 .0381 
PSQI-A 1 10 1.84 .155 . 205 
 
Table 22. 
Repeated-Measures Analysis of Variance for Effects of Cognitive Behavioral Treatment of 
Insomnia (Condition X Time) on Mood Symptoms and Daytime Functioning 
Variable 
 
Df Error df F ηp2 p 
Depression 
(PHQ-9) 
 
1 21 16.17 .435 .001 
Overall 
Distress 
(POMS) 
 
1 24 8 .25 .009 
Depression 
(POMS) 
 
1 24 6.5 .214 .017 
Tension 
(POMS) 
 
1 24 5.69 .192 .025 
Vigor 
(POMS) 
 
1 24 .039 .002 .845 
Anger 
(POMS) 
 
1 24 5.28 .180 .031 
Confusion 
(POMS) 
 
1 24 9.36 .281 .005 
Fatigue 
(POMS) 
1 24 5.23 .179 .031 
 
Table 23.  
Repeated-Measures Analysis of Variance for Effects of CBT-I over time for Mood Symptoms 
and Daytime Functioning (POMS and PHQ) 
Variable 
 
Df Error df F ηp2 p 
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   Treatment Condition   
Depression 
(PHQ-9) 
 
1 13 28.9 .697 .000 
Overall 
Distress 
(POMS) 
 
1 13 6.12 .320 .028 
Depression 
(POMS) 
 
1 13 3.2 .198 .097 
Tension 
(POMS) 
 
1 13 6.54 .335 .024 
Anger 
(POMS) 
 
1 13 4.94 .275 .045 
Confusion 
(POMS) 
 
1 13 7.79 .375 .015 
Fatigue 
(POMS) 
1 13 5.9 .312 .03 
   Waitlist Control   
Depression 
(PHQ-9) 
 
1 8 1.23 .133 .301 
Overall 
Distress 
(POMS) 
 
1 11 2.38 .177 .152 
Depression 
(POMS) 
 
1 11 3.44 .238 .091 
Tension 
(POMS) 
1 11 .752 .064 .404 
Anger 
(POMS) 
 
1 11 1.23 .101 .291 
Confusion 
(POMS) 
 
1 11 3 .214 .111 
Fatigue 
(POMS) 
1 11 .768 .065 .400 
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Table 24. 
Repeated-Measures Analysis of Variance: Effects of CBT-I on Objective Measures of Sleep 
(Actigraphy) over time (Treatment Group) 
Variable 
 
Df Error df F ηp2 p 
Sleep 
Efficiency 
 
1 9 7.25 .446 .025 
Sleep Onset 
Latency 
 
1 9 4.88 .352 .054 
Total Sleep 
Time 
 
1 9 .056 .006 .82 
Wake After 
Sleep Onset 
1 9 7.18 .444 .025 
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